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ABSTRACT 
Understanding mechanisms of beta cell susceptibility to type 1 diabetes  
YoungJung Rachel Kim 
 
Type 1 diabetes mellitus (T1D) is an autoimmune disease characterized by the 
inflammation of the insulin-producing pancreatic beta cells, eventually leading to beta 
cell loss and the inability to maintain glucose homeostasis. Understanding the 
mechanisms of beta cell-intrinsic factors that influence the maintenance of cellular 
defenses and contribute to cell death when deregulated will be crucial in efforts to treat or 
prevent beta cell loss in individuals who are prone to autoimmunity. Through my thesis 
work, I have investigated beta cell-specific etiologies of T1D through both a candidate-
based approach using beta cell-specific deletion of a susceptibility gene and an unbiased 
global exploration of beta cell factors that regulate the predisposition to insulitic injury.  
Protein tyrosine phosphatase N2 (PTPN2) is a T1D candidate gene that has been 
shown to be critical for modulating inflammation by regulating T cell activation. PTPN2 
is also highly expressed in human and murine beta cells and it has been shown to be 
critical for beta cell function in vivo and inhibit inflammatory stimuli-mediated beta cell 
apoptosis in vitro, suggesting that PTPN2-mediated defense against inflammation is two-
pronged – negative regulation of inflammatory immune cells and elevation of a beta cell-
intrinsic defense. To examine whether PTPN2 regulates beta cell loss upon cytotoxic 
stimuli by bolstering beta cell defense mechanisms in vivo, I deleted PTPN2 in the beta 
cells (Ptpn2 βKO) and subjected the mice to the diabetogenic agent streptozotocin (STZ). 
Animals deficient in beta cell PTPN2 are more susceptible to STZ-induced diabetes and 
have poor survival due to hyperglycemia. While investigating the mechanism of PTPN2-
mediated beta cell defense, I have discovered that PTPN2 interacts with pyruvate kinase 
M2 (PKM2), a key metabolic enzyme that normally resides in the cytosol. In response to 
STZ, PKM2 translocates to the nuclei of diabetic beta cells, and the lack of PTPN2 
results in the hyper-accumulation of nuclear PKM2, suggesting that PTPN2 mediates 
nuclear export of PKM2 in stressed beta cells. In the nucleus, PKM2 mediates the 
transcriptional activation of key proapototic genes, which is attenuated when I modulate 
nuclear PKM2 ex vivo, in effect reconstituting the function of PTPN2. Together, 
deregulation of PTPN2-mediated nuclear export of PKM2 leading to excessive 
transcriptional activation of proapoptotic genes may be the mechanism for exacerbated 
diabetes in the Ptpn2 βKO mice.  
To identify novel candidates that function in the beta cells to influence beta cell 
susceptibility to insulitic injury, I established RNA transcriptome and CpG dinucleotide 
methylome profiles of islets isolated from insulitis-susceptible NOD and insulitis-
resistant NOR mice, prior to the onset of insulitis. Integrating these profiles with the 
genes nested in the human diabetic loci from the genome-wide association studies, I 
identified several novel candidate genes that may be involved in T1D pathogenesis in a 
beta cell-specific manner. Moreover, I also examined non-CpG methylation, which 
appears to influence gene expression independently of CpG methylation.  
Collectively, my studies have expanded the understanding of beta cell-specific 
factors that regulate cellular defense to insulitis and may have expanded the therapeutic 
possibilities by implicating PKM2, inhibition of which is the focus of many cancer 
therapy research.   
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Type 1 diabetes 
Diabetes mellitus is a class of endocrine disorders characterized by high levels of 
blood glucose due to a deficiency in or resistance to the key metabolic hormone insulin. 
Type 1 diabetes (T1D) develops from the autoimmune destruction of insulin producing 
beta cells in the pancreatic islets, whereas dysfunctional beta cells combined with insulin-
resistant peripheral tissues lead to type 2 diabetes (T2D). According to the American 
Center for Disease Control National Diabetes Statistics Report 2014, 29.1 million people 
in the United States – an astounding 9.3% of the population – were living with diabetes in 
2012, with 1.7 million new cases of diabetes diagnosed within the calendar year. Patients 
with hyperglycemia are usually diagnosed with diabetes when they present with a triad of 
classic clinical signs of excessive thirst (polydipsia), frequent urination (polyuria), and 
increased hunger (polyphagia). Left untreated, diabetes can lead to dangerous health 
complications such as heart disease, kidney failure, stroke, blindness, and death. Aside 
from being the seventh leading cause of death in the United States, diabetes poses a 
significant economic burden, costing the United States economy $245 billion in 2012 
(CDC, 2014). As of 2014, the cure for diabetes remains elusive, and it is of great interest 
to prevent disease by identifying risk factors. 
Although it is widely accepted that diabetes can manifest a spectrum of both T1D 
and T2D characteristics, islet autoantibodies can be detected in about 10% of all diabetes 
cases, which establishes autoimmune diagnosis. Previously known as juvenile diabetes, 
T1D is more commonly diagnosed in younger people, but disease initiation can occur at 
any age in susceptible individuals (ADA, 2014). The main treatment option is lifelong 
insulin replacement therapy, which requires close medical supervision, and because 
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peripheral tissues are sensitive to insulin action in T1D, variability in insulin absorption 
can lead to dangerous episodes of hypoglycemia that can substantially impair the quality 
of life (Frier, 2008; Pickup, 2012). Recent advances in glucose-responsive insulin 
(SmartInsulin) and artificial pancreas may mitigate the complications but diabetic 
patients still require lifelong clinical monitoring. Other treatment approaches employ 
immune modulators or molecules that protect beta cell function, but successful 
suppression of the beta cell-specific autoimmunity without rendering the patient 
immunocompromised remains a challenge. Furthermore, once the immune system is 
primed against self-antigens on beta cells, beta cell death is progressive and irreversible, 
and after prolonged disease progression, patients require islet transplantation. Thus, it is 
desirable to prevent or intervene prior to significant beta cell loss, which may be 
accomplished by a better understanding of disease etiology. 
 
 
Current understanding of T1D etiology 
The clinical manifestation of T1D is the consequence of sustained autoimmune 
attack on beta cells and does not occur until a significant portion of beta cell mass has 
been lost (van Belle et al., 2011). The most well known model of T1D timeline was 
proposed by Eisenbarth in 1986 (Eisenbarth, 1986). This model proposes that individuals 
with genetic susceptibility are exposed to variable environmental triggers. In the event 
that an individual possesses genetic susceptibility to T1D and is exposed to diabetogenic 
triggers, the combinatorial effect can initiate islet autoantibodies, leading to a linear 
decline in beta cell mass and progressive hyperglycemia (Fig. 1-1) It has now been 
established that the length of time between T1D initiation and clinical onset is highly 
variable. This variability may be due to the degree of genetic susceptibility including 
!
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penetrance of certain alleles and the cumulative effect of several susceptibility alleles, as 
well as the severity of immune response to one or more environmental triggers. 
 
Genetic factors 
Even with the same environmental triggers, only the individuals with genetic 
susceptibility eventually develop T1D. A significant genetic predisposition to T1D is 
conferred by several insulin-dependent diabetes mellitus (IDDM) loci. First, IDDM1 is 
the chromosomal region 6p21 commonly known as the human leukocyte antigen (HLA) 
complex, which contains more than 200 genes and is thought to account for most of the 
genetic susceptibility to T1D (Concannon et al., 2009; Nerup et al., 1974). The HLA 
complex is the human version of the major histocompatibility complex (MHC) 
molecules, which present cellular antigens to the immune cells. Class I molecules (HLA-
A, B, and C) are on all nucleated cells and class II molecules (HLA-DP, DQ, DR, etc.) 
are only present on antigen presenting cells of the immune system. Class I alleles seem to 
confer a modest but consistent risk for T1D, while individuals carrying the class II 
DR3/4-DQ2/8 risk haplotype are at an extreme risk, as much as 55% risk of disease by 
the age of 12 (Aly et al., 2006).  
Another well studied locus is the IDDM2 on chromosome 11p15, which contains 
the insulin (INS) gene (Bell et al., 1984). The promoter of the INS gene contains variable 
number of tandem repeat polymorphisms, which determines insulin gene expression in 
the thymus. Shorter repeats correlate with reduced gene expression and the consequent 
reduction in the elimination of insulin-reactive T cells in the thymus leave these 
individuals at a higher risk for T1D (Vafiadis et al., 1997).  
!
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Other susceptibility genes confer significant comorbidity with a number of 
autoimmune disorders such as rheumatoid arthritis, autoimmune thyroiditis, and 
inflammatory bowel disease, because they function in suppressing T cell hyperactivity. 
For instance, individuals with polymorphisms in the cytotoxic T-lymphocyte protein 4 
(CTLA4) gene, which functions in the negative regulation of T cell receptor (TCR) 
activation, have higher T1D risk because of the reduced expression of soluble CTLA4 
(Chikuma et al., 2003; Nistico et al., 1996; Ueda et al., 2003). Additionally, a 
polymorphism in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene, 
which encodes the lymphoid protein tyrosine phosphatase (LYP), has been shown to be a 
gain-of-function mutation producing a more catalytically active protein phosphatase, 
resulting in hypophosphorylation and hypoactivation of the TCR signaling (Vang et al., 
2005).  
Many of the above mentioned susceptibility genes have been identified through 
genome-wide association studies (GWAS), which seek to identify relevant small 
nucleotide polymorphisms (SNPs) that occur more frequently in individuals with disease 
(Pearson and Manolio, 2008; Wellcome Trust Case Control, 2007). The association 
between genes and disease is an unbiased approach to efficiently identify novel genetic 
loci shared by unrelated individuals in complex polygenic diseases such as T1D. 
However, rigorous candidate-based inquiry into the functional consequences of disease-
associated SNPs has been difficult because the SNPs may individually confer mild risk to 
disease without the complementary contribution of disease-triggering environment and 
other genetic factors. Furthermore, most of the SNPs reside in noncoding regions and the 
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resultant variations in gene expression are cell-type specific and mostly unknown in 
tissues with rare availability such as the pancreatic islets (Ward and Kellis, 2012).  
 
Environment of the organism 
Underlying genetic susceptibility leads to clinical manifestation of T1D due to a 
variety of environmental triggers that can be broadly classified as either infectious or 
dietary. As early as 1926, seasonal variation has been documented as a factor in T1D 
onset (Adams, 1926). Later studies have attributed this to seasonal variations in viral 
infections such as Coxsackie’s B4 virus. Other viruses including cytomegalovirus, rubella 
virus and mumps virus have also been implicated (van Belle et al., 2011). Viral agents 
may activate autoimmunity through peptides that mimic human autoantigens (molecular 
mimicry), by priming the diversification of TCR during inflammation (epitope 
spreading), or through the expression of superantigens that dominantly activate non-
specific T cells (Wucherpfennig, 2001). Bacterial imbalance in the gut microbiome may 
also trigger T1D by affecting gut permeability to infectious agents (Murri et al., 2013; 
Wen et al., 2008). However, while infection and T1D may coincide, depending on the 
context, infection can also confer protection from disease, and limiting the exposure to 
infectious agents can increase disease incidence, commonly referred to as the “hygiene 
hypothesis” (Bach, 2002; Okada et al., 2010). For instance, children with older siblings at 
home or children who attend a day-care center have a lower incidence of T1D than 
children with lesser degree of social mixing, due to increased exposure to infectious 
agents at an early age (McKinney et al., 2000). 
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Dietary variations among individuals may also account for variable T1D risk in 
susceptible individuals. First, early introduction to cow’s milk possibly coupled with 
short duration or lack of breastfeeding increase the risk for T1D. Cow’s milk has a higher 
albumin content, and antibodies to albumin cross react with beta cell surface protein 
(Karjalainen et al., 1992), and breast milk can be protective due to high content of 
antimicrobial lactoferrin and immunoglobin A (Patelarou et al., 2012). However, this 
topic has been rather controversial (Norris et al., 1996), and others have proposed that 
increased immunity to cow’s milk may just be a reflection of impaired mucosal immune 
function (Harrison and Honeyman, 1999). Additional dietary components such as omega-
3 fatty acids (Norris et al., 2007) and gluten (MacFarlane et al., 2003) may also increase 
autoimmunity to islet antigens. Furthermore, dietary vitamin D can be protective 
(Mathieu et al., 2005), and gene products that affect vitamin D metabolism can increase 
T1D risk (Bailey et al., 2007). This may be partly attributed to immunomodulatory effect 
of vitamin D (D'Ambrosio et al., 1998). Non-dietary sources of vitamin D such as the 
sunlight is also important, as the highest incidence of T1D occurs in the northernmost 
hemisphere, in countries like Sweden where the hours of sunshine are limited (van Belle 
et al., 2011). 
Genetic variations may interact directly with environmental stressors, as in the 
case of PTPN22 polymorphism and cow’s milk exposure (Lempainen et al., 2009). 
However, even without genetic variations, the environment can produce variable 
phenotypes by modifying gene expression without directly changing the DNA sequence. 
One example is in the monozygotic twins. Despite the fact that they have an identical 
genetic makeup, identical twins do not have the same risk for T1D at a single time point 
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(Barnett et al., 1981). Although it has been shown that most of the discordant twins of 
T1D patients eventually progress to T1D with a longer follow up (Redondo et al., 2008), 
the fact that islet autoantibodies may appear some thirty years later in one identical twin 
suggests altered gene expression from identical genetics, also known as epigenetics.  
 
Environment of the genome 
Epigenetic modifications such as histone modifications and DNA methylation can 
change chromatin structure and limit DNA accessibility, thereby regulating gene 
expression. First, gene expression can be altered by the dynamic modifications of 
histones that change chromatin architecture. Eukaryotic chromatin is composed of 
nucleosome subunits, which consist of eight molecules of core histone proteins wrapped 
around by DNA strands. It is well established that the addition of acetyl groups to histone 
cores at select lysine residues can facilitate transcription factor access by unwinding the 
condensed chromatin. Conversely, deacetylation can lead to chromatin condensation and 
gene repression (Grunstein, 1997). Other posttranslational modifications of histones 
include methylation, phosphorylation, or ubiquitination, and different combination of 
these modifications, commonly known as the histone code, is linked with specific 
biological functions including gene expression, gene silencing, and mitosis (Strahl and 
Allis, 2000). Immune cells from T1D patients show differences in histone modification of 
T1D gene promoters such as H3K9 methylation in the promoter of CTLA4 locus (Miao et 




DNA methylation is the addition of a methyl group to cytosine residues preceding 
guanine, known as CpG dinucleotides. Clusters of CpG dinucleotides, known as CpG 
islands, can occur in regulatory regions of genes such as promoters. Hypermethylation of 
CpG islands correlates with transcriptional silencing events such as imprinting and X 
chromosome inactivation (Bird, 2002). The temporal and causative relationship between 
transcriptional silencing and CpG methylation is unclear. There is evidence that 
methylated CpG islands inhibit transcription initiation (Kass et al., 1997; Venolia and 
Gartler, 1983), but it has also been shown that methylation of Hprt gene promoter CpG 
sites happens after X inactivation, suggesting that DNA methylation may play a 
secondary role to maintain the repression of transcription (Lock et al., 1987). 
Nonetheless, DNA methylation is an important posttranslation modification.  
Aside from its role in gene silencing, CpG methylation can be used as a 
biomarker of T1D. One group showed that a subset of immune cells (CD14+ monocytes) 
from discordant monozygotic twins showed differential methylation patterns in 132 CpG 
sites, including an HLA gene. Also, differences in these T1D-associated methylation 
variable sites seem to arise early in the disease process (Rakyan et al., 2011). B cells from 
discordant twin pairs also show differential CpG methylation patterns, including T1D 
genes such as HLA-DOB and INS (Stefan et al., 2014). Another group identified a pattern 
of 3 hypomethylated CpG sites in the INS promoter unique to the blood samples of 14% 
of T1D patients (Fradin et al., 2012). Hypomethylation within the INS gene was also seen 
in the sera of newly diagnosed T1D patients, and this was attributed to the presence of 
dead beta cell DNA (Akirav et al., 2011; Husseiny et al., 2014). Thus, DNA methylation 
marks are present in both the immune cells and targeted beta cells in T1D. However, 
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much like the relationship between methylation and transcriptional silencing, it is not 
known whether CpG methylation can initiate T1D pathogenesis, or whether it is a 
product of T1D disease process. It should be noted that DNA methylation can certainly 
engender human disease. For example, methylated cytosine can expedite the transition of 
cytosine to thymine, functioning as an endogenous mutagen, which can be carcinogenic if 
it occurs in tumor suppressor genes (Rideout et al., 1990). This may be subject to direct 
environmental influences, such as diets lacking methyl group donors like methionine, 
which can lead to liver cancer (Cooney et al., 2002; Poirier, 2002). Moreover, our current 
understanding of DNA methylation is mostly limited to CpG sites, but non-CpG 
methylation has also been reported in both embryonic and somatic cell types (Guo et al., 
2014; Ramsahoye et al., 2000), and it is of interest to see physiological ramifications of 
non-CpG methylation.  
 
Studies in murine models of T1D 
Advancement in the understanding of T1D pathophysiology was set in motion 
with the discovery of murine models of spontaneous diabetes in the late 1970s and early 
1980s. The non-obese diabetic (NOD) mouse strain was discovered during the inbreeding 
of the cataract-prone mice in Japan (Makino et al., 1980), and outbred colonies of the 
Wistar rat at the Bio-Breeding (BB) Labs in Canada displayed spontaneous diabetes 
(Nakhooda et al., 1977). The NOD mouse in particular, displayed many similarities with 
the human T1D including genetic and environmental involvement, and has become the 
main model of T1D (Joost et al., 2012).  
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The NOD mouse model has been invaluable in identifying key pathological 
features of the human disease, but many similarities and differences exist. Autoimmune 
diabetes in the NOD mouse is spontaneous and progresses in stages, beginning with 
immune cells being attracted to the pancreatic islets around 4-8 weeks, infiltrating and 
destroying beta cells starting at 12 weeks, eventually leading to overt diabetes by 16-24 
weeks (Fig. 1-2) (Anderson and Bluestone, 2005). This stage-to-stage progression of 
worsening inflammation and heightened immune response is different from humans in 
which disease process is more chronic and subtle. Diabetes incidence in the NOD mouse 
is highly variable and depends on the pathogen levels of the environment, which may be 
similar to the human “hygene hypothesis” (Ohsugi and Kurosawa, 1994). It is also 
sexually dimorphic as most of the female mice develop diabetes by 30-40 weeks, but the 
incidence in males is significantly lower and it has been established that this is due to 
differing gut microbiome colonization that is androgen-dependent (Fox, 1992; Markle et 
al., 2013). This is different from humans, where incidence is not dependent on gender.  
The advantage of using murine models of disease is that many therapeutic 
approaches may be assessed for safety and efficacy, which is required prior to initiating 
human trials, and that genetics can be utilized to better understand the molecular 
mechanisms of disease. T1D has been successfully prevented, delayed, or reversed in the 
NOD mice in countless ways (Ablamunits et al., 2012; Emamaullee et al., 2009; Fiorina 
et al., 2008; Grinberg-Bleyer et al., 2010; Jin et al., 2012; Perone et al., 2009; Tian et al., 
2009; Vergani et al., 2010; Yi et al., 2012; Zhao et al., 2009). However, this has not been 
attainable in humans, possible due to underlying differences in humans and mice.  
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Aside from models of spontaneous diabetes, chemicals such as streptozotocin 
(STZ) or alloxan can rapidly induce beta cell death. STZ is an antibiotic from 
Streptomyces achromogenes that can selectively enter beta cells via the GLUT2 glucose 
transporter utilizing its glucose side chain (Fig. 1-3) (Schnedl et al., 1994; Vavra et al., 
1959). Inside the beta cell, STZ can alkylate DNA using its methylnitrosourea moiety, 
leading to DNA fragmentation and the generation of nitric oxide (NO), and genotoxic 
beta cell death ensues (Lenzen, 2008; Yamamoto et al., 1981). Furthermore, STZ is an 
analogue of N-acetylglucosamine, which mimics and competes with the O-linked beta-N-
acetylglucosamine (O-GlcNAc) modifications of cellular proteins for the beta-N-
acetylglucosaminidase (O-GlcNAcase), an enzyme that cleaves O-GlcNAc (Konrad et 
al., 2001; Roos et al., 1998). Beta cells express unusually high levels of O-GlcNAc 
modifications, and transgenic mice with impaired levels of O-GlcNAc are protected from 
STZ-induced diabetes (Liu et al., 2000), but this has been controversial because increases 
in O-GlcNAc levels due to O-GlcNAcase inhibitors did not result in beta cell damage 
(Gao et al., 2000). In either case, STZ proves to be a potent beta cell toxin, valuable in 
the study of beta cell death in diabetes.  
STZ can be used at different doses to induce diabetes. At low doses, multiple 
sequential daily injections over several days are required to achieve slow-onset modest 
hyperglycemia within two weeks that involves cellular immune response and the 
induction of apoptosis (McEvoy et al., 1984; O'Brien et al., 1996). At higher doses of 
STZ, a single injection can rapidly achieve significant hyperglycemia in 48 hours through 
the induction of cell death without involving the immune system (Deeds et al., 2011; 
Junod et al., 1969). The exact mode of STZ induced beta cell death without the immune 
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system, at least in culture, seems to be primarily via the activation of apoptosis in short-
term low doses, and a combination of necrosis (22%) and apoptosis (17%) at higher 
doses (Morgan et al., 1994; Saini et al., 1996). Precise in vivo mode of STZ is most likely 
a combination of apoptosis and necrosis. One study used Annexin V as an early marker 
of apoptosis and determined that 48 hours after STZ-administration, there is significant 
apoptosis in both low dose (2%) and high dose (26%) models of diabetes in vivo 
(Medarova et al., 2005).  
At either dose, STZ-induced diabetes is highly dependent on mouse strain 
background and gender (Deeds et al., 2011; Leiter, 1982). In contrast to the NOD model, 
where female mice are more prone to diabetes, in the STZ model, estrogens protect beta 
cells from apoptosis, in both low and high doses (Le May et al., 2006). Other factors such 
as circadian rhythm and diet, as well as methods of STZ preparation and administration, 
can be attributed to highly variable results in the onset and severity of diabetes (Deeds et 
al., 2011). Despite this, STZ is an invaluable tool to study diabetes without the need to 
wait for the onset of spontaneous diabetes. 
A number of other mouse models of diabetes have been employed and are 
reviewed elsewhere (Van Belle et al., 2009). Given the complexity of T1D and the 
differences in humans and mice, no single mouse model can emulate the human T1D 
with perfection. However, the use of mouse models is efficacious and indispensable 






Beta cell death in type 1 diabetes 
In T1D, pancreatic beta cells are assaulted over the course of years by the 
autoimmune machinery after which beta cells start to die. Central to the rationale behind 
my work is the idea that T1D results from the failure of beta cells to mount sufficient 
defense mechanisms in response to the immune attack. Certain beta cells may be more 
prone to death even with the same degree of immune stimuli, in that beta cells themselves 
have a defense mechanism that is variably influenced by various T1D-triggering genes 
and environment. The fate of beta cell survival or death may be a choice implemented by 
the beta cells themselves, assisted by immune agents. To better understand beta cell 
response to the immune system, it is important to outline some of the immune events in 
T1D pathogenesis. 
Initiation of immune events can be primed by the release of beta cell antigens 
upon beta cell death, which can be a result of a viral event or a sporadic physiological 
event. These antigens circulate and are taken up by antigen presenting cells to be 
presented to the T cells. Normally during immune cell development, T cells that 
recognize “self” beta cell antigens are effectively eliminated in the thymus by a process 
called negative selection. This is known as immune tolerance. However, when self-
antigen recognizing T cells manage to escape thymic negative selection, abnormal 
recognition of self-antigens as deleterious foreign particles leads to an activation of the 
autoimmune machinery (Calderon and Unanue, 2012).  
Decreased tolerance to beta cell antigens leads to the inflammation of the 
pancreatic islets, known as insulitis, first observed in 1965 (Gepts, 1965). Two of the key 
immune cells comprising the insulitic lesions include activated macrophages and T 
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lymphocytes that can produce a number of inflammatory cytokines such as interleukin 1 
beta (IL-1β), tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), as well as 
cytotoxic free radicals (von Herrath, 2009). The inflammatory cytokines can further 
activate macrophages and attract T cells, becoming a positive feedback loop that further 
propagates the inflammatory response. Aside from cytokine production, T cells can 
directly participate in the extrinsic pathway of beta cell death by producing the Fas ligand 
(also known as CD95 or FasL) and the TNF related apoptosis inducing ligand (TRAIL), 
which can lead to caspase activation and cell death independently of intracellular cell 
death programming. Furthermore, activation of the TCR can lead to the release of toxic 
granules containing perforin and granzyme. Perforin perforates the target cells by 
opening a pore in the cell membrane, which allows for the granzyme to enter the cytosol, 
where it can activate cell death in synergy with the inflammatory cytokines via the 
intrinsic pathway, also known as mitochondrial pathway of cell death. This involves a 
number of other factors such as the endoplasmic reticulum (ER) stress and the 
intracellular balance of B-cell lymphoma 2 (BCL-2) family proteins that control the 
permeability of mitochondrial membrane. Imbalance in the BCL-2 proteins can lead to 
the release of cytochrome c from the mitochondria to the cytoplasm, which leads to the 
activation of programmed cell death (Delaney et al., 1997; Eizirik and Mandrup-Poulsen, 
2001).  
The exposure of the beta cells to a combination of pro-inflammatory cytokines 
leads to dramatic changes in gene expression in human and murine beta cells (Cardozo et 
al., 2001a; Eizirik et al., 2012; Kutlu et al., 2003). Genes that are upregulated include 
stress response genes that can be either protective or deleterious for beta cell survival. 
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Furthermore, different genes that function in the same category of stress response can be 
upregulated and downregulated, adding to the complexity of the beta cell response. For 
example, defense repair genes encoding clusters of defense enzymes including 
metallothionein or superoxide dismutase were induced, but glutathione peroxidase genes 
were downregulated in cytokine treated beta cells (Cardozo et al., 2001a; Cardozo et al., 
2001b).  
One of the main transcription factors that are activated in response to IL-1β is 
nuclear factor kappa B (NF-κB). Suppressing the activation of NF-κB through the 
inhibitory factor kappa B (IκB) can prevent cytokine-induced apoptosis (Giannoukakis et 
al., 2000; Heimberg et al., 2001). NF-κB can induce the expression of stress genes such 
as CCAAT/enhancer binding protein (C/EBP) homologous protein (Ddit3 or CHOP) that 
can induce ER stress, and at the same time downregulate genes critical for beta cell 
function and the maintenance of differentiated beta cell characteristics, such as 
pancreatic and duodenal homeobox 1 (Pdx1). The effect of NF-κB can be through a 
direct transcriptional activation or secondary to the expression of the inducible nitric 
oxide synthase (iNOS) gene, which generates cytotoxic NO in the islets (Darville and 
Eizirik, 1998). Cytokine-induced NO generation in the beta cells requires the activation 
of protein kinases including p38 mitogen-activated protein kinase (MAPK) and 
extracellular signal-regulated kinase (ERK) (Larsen et al., 1998; Nishiki et al., 2013), and 
NO accumulation leads to an upregulation of the tumor suppressor protein p53, which is 
toxic to beta cell survival (Hoshino et al., 2014).  
Gene expression changes in response to cytokines can also occur through the 
activation of receptor tyrosine kinase signaling. IFN-γ can bind to and activate janus 
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kinase 1 and 2 (JAK1/2) on the beta cell surface, and downstream of this, signal 
transducer and activator of transcription 1 (STAT1) becomes phosphorylated. 
Phosphorylated STAT1 can dimerize and migrate to the nucleus, where it can induce 
transcription of various genes, including iNOS (Eizirik and Mandrup-Poulsen, 2001). 
STAT1 upregulates the expression of a pro-apoptotic gene death protein 5 (Dp5, also 
known as activator of apoptosis harakiri or Hrk), and knockdown of STAT1 protected rat 
beta cells from cytokine-induced apoptosis (Moore et al., 2011). This was accompanied 
by the retention of key beta cell gene expression including Pdx1 and Ins, suggesting that 
STAT1 is perhaps the master regulator of beta cell apoptosis. In response to IFN-γ and 
TNF-α, STAT1 also upregulated BCL-2-interacting mediator of apoptosis (Bim) 
expression to mediate apoptosis, and silencing Bim protected against apoptosis (Barthson 
et al., 2011).  
Induction of stress-activated genes in response to cytokines is followed by the ER 
stress response, which depletes the calcium stores in the ER (Cardozo et al., 2005; 
Chambers et al., 2008). Disruption of calcium homeostasis as well as the accumulation of 
the unfolded proteins leads to a sequence of compensatory mechanisms to restore the ER 
balance, which includes decreasing protein translation and degradation of unfolded 
proteins. Unmitigated ER stress leads to apoptosis. Cytokines can lead to ER stress via 
the generation of NO (Oyadomari et al., 2001) and the upregulation of p53 that can 
induce p53 upregulated modulator of apoptosis (PUMA) (Gurzov et al., 2010; Hoshino et 
al., 2014).  
Key proteins that are upregulated in response to STAT1 signaling or ER stress 
including DP5, BIM, and PUMA, belong to a special class of the BCL-2 family 
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members, known as the BCL-2 homology 3 (BH3)-only proteins. Other members of the 
BCL-2 family contain multiple BCL-2 homology domains and can be classified as pro-
survival or pro-apoptotic (Fig. 1-4). In response to apoptotic stressors, BH3-only proteins 
can be upregulated or activated by posttranslational modifications, and they can facilitate 
apoptosis by inhibiting pro-survival molecules like BCL-2, thereby freeing the pro-
apoptotic molecules such as BCL-2-associated X protein (BAX) and BCL-2 antagonist 
killer (BAK) to form oligomers on the outer membrane of the mitochondria, leading to 
mitochondrial permeabilization and cytochrome c release. BH3-only molecules can also 
interact directly with BAX, leading to conformational changes that effect apoptosis 
(Czabotar et al., 2014; Lomonosova and Chinnadurai, 2008).  
Together with inflammatory cytokines and cytotoxic perforin and granzymes, the 
complex machinery of beta cell apoptosis can be initiated, but beta cells themselves may 
be more prone to injury compared to other cell types, which may be a factor in lowering 
the threshold of apoptosis initiation. First, beta cells express unusually low levels of 
antioxidant enzymes such as glutathione peroxidase (~5% of liver cells), which may 
suggest compromised defense mechanisms (Tiedge et al., 1997). Beta cells also have a 
high rate of protein turnover and protein synthesis, being a secretory cell type, and may 
be more susceptible to ER stress (Harding et al., 2001). In fact, in the NOD mouse model, 
ER stress precedes significant immune attack suggesting that beta cells are innately more 
predisposed to stress (Tersey et al., 2012). Lastly, many candidate genes from the human 
T1D GWA studies have been widely studied in the context of immune signaling, but it is 
likely that these genes play a role in the beta cells themselves. In support of this, the 
majority of the candidate genes are expressed in the human islets, and the expression of 
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these genes are further induced with pro-inflammatory cytokines, suggesting that beta 
cells may contribute to their own demise (Eizirik et al., 2012). 
 
Type 1 diabetes candidate gene PTPN2 
Overview 
One of the T1D candidate genes identified by GWAS is protein tyrosine 
phosphatase non-receptor type 2 (PTPN2, also known as T cell protein tyrosine 
phosphatase, or TC-PTP), which encodes a member of the protein tyrosine phosphatase 
(PTP) superfamily (Todd et al., 2007). The superfamily of PTPs defines intracellular 
phosphotyrosine patterning in concert with protein tyrosine kinases (PTKs), and an 
imbalance in the PTP-ome can lead to devastating biological outcomes such as diabetes, 
cancer, autism, myopathy, and epilepsy (Alonso et al., 2004). In the human genome, there 
are 107 PTPs with the same active site motif HCX5R but of varying substrate specificity 
dictated by the catalytic domain architecture, subcellular localization, and 
posttranlastional modifications. Of these, subcellular localization is in part determined by 
protein sequence: in addition to the PTP domain, receptor type PTPs contain extracellular 
and transmembrane domains, whereas the non-receptor type PTPs contain terminal 
localization domains that target the PTP to specific subcellular locations.  
PTPN2 is one of the two non-transmembrane non-receptor type classical PTPs, 
along with PTPN1, encoded by protein tyrosine phosphatase non-receptor type 1 
(PTPN1, also known as PTP1B) (Cool et al., 1989; Tonks et al., 1988). PTPN2 has two 
isoforms: the major isoform TC45 (45 kDa) which has a nuclear localization signal, and 
the minor isoform TC48 (48 kDa) which is tethered to the endoplasmic reticulum 
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(Soulsby and Bennett, 2009). The substrates of nuclear TC45 include janus kinases (JAK) 
1 and 3 (Simoncic et al., 2002), and signal transducer and activator of transcription 
(STAT) 1 and 3 (ten Hoeve et al., 2002; Yamamoto et al., 2002). Upon specific 
stimulation, nuclear TC45 can exit the nucleus (Fig. 1-5) (Lam et al., 2001) and 
dephosphorylate non-nuclear substrates such as epidermal growth factor receptor (EGFR) 
(Tiganis et al., 1998) and insulin receptor (IR) (Galic et al., 2003), which are also targeted 
by the less abundant TC48.  
PTPN1 has a single isoform that is targeted to the endoplasmic reticulum 
(Frangioni et al., 1992). There is a partial overlap between substrates of PTPN1 and 
PTPN2 including STAT3 (Lund et al., 2005), EGFR (Flint et al., 1997), and IR (Kenner 
et al., 1996), which can be attributed to the 74% sequence identity in the catalytic 
domains of PTPN1 and PTPN2 (Iversen et al., 2002). However, PTPN1/PTPN2 chimera, 
where the PTPN2 catalytic domain was fused to the localization domain of PTPN1, does 
not interact with the same substrates as PTPN1, suggesting unique substrate specificity of 
the PTP domains despite the sequence similarities (Tiganis et al., 1998).  
 
Lessons from the PTPN2 knockout mouse studies 
Distinct substrate specificity and differential tissue expression patterns in the two 
closely related PTPs are highlighted by different phenotypes associated with the 
knockout mice. Whole body Ptpn1 knockout mice are healthy and show increased insulin 
sensitivity and resistance to obesity by regulating insulin receptor signaling in muscle and 
liver (Elchebly et al., 1999; Klaman et al., 2000), indicating that Ptpn1 could be an 
attractive metabolic target for treating obesity and T2D (Moller et al., 2000). In contrast, 
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whole body Ptpn2 knockout mice die by 5 weeks after birth due to defects in 
hematopoiesis and significant induction of systemic inflammation (Heinonen et al., 2004; 
You-Ten et al., 1997). Due to this early lethality of the Ptpn2 null mice, a number of 
conditional null mice have been generated to study the in vivo functions of PTPN2 in 
different tissues.  
To study the role of PTPN2 in insulin signaling, mice with Ptpn2 deletion in the 
key organs of insulin action (muscle, liver, or bone) have been generated. The muscle-
specific knockout of Ptpn2 has no effect on insulin response and glucose homeostasis, 
even upon high fat diet (HFD) challenge, suggesting muscle PTPN2 is dispensable for the 
regulation of insulin receptor signaling (Loh et al., 2012). Liver-specific Ptpn2 
conditional deletion led to increased obesity and insulin resistance through 
hyperactivation of insulin-mediated STAT5 signaling (Gurzov et al., 2014). Moreover, 
the activation of STAT5 signaling with HFD led to the inactivation of PTPN2 by the 
oxidation of the PTPN2 catalytic site, creating a de facto liver-specific Ptpn2 deletion in 
the control mice without the conditional allele, further compounding obesity and insulin 
resistance. It has also been shown that PTPN2 maintains whole body energy metabolism 
through the negative regulation of insulin receptor signaling in osteoblasts. Osteoblasts 
secrete the hormone osteocalcin that leads to insulin secretion and increased whole-body 
insulin sensitivity (Ferron et al., 2008). In turn, insulin signaling in osteoblasts leads to 
increased osteocalcin activity, further promoting insulin secretion and increased bone 
resorption by osteoclasts (Ferron et al., 2010). Therefore, PTPN2 functions as a negative 
regulator of insulin signaling in osteoblasts, and osteoblast-specific Ptpn2 conditional 
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deletion mice exhibit increased osteocalcin activity, bone resorption, and insulin 
sensitivity (Zee et al., 2012).  
Energy homeostasis is governed not only by insulin from the beta cells but also by 
leptin from the adipocytes (Halaas et al., 1995). In addition to its role in insulin signaling, 
PTPN2 has also been implicated as a negative regulator of leptin signaling. 
Hypothalamus-specific Ptpn2 deletion hyperactivates STAT3, a signal transducer of 
leptin, and this leads to increased leptin signaling manifested by decreased food intake 
and energy expenditure, along with increased insulin sensitivity and glucose tolerance 
(Loh et al., 2011).  
Beyond the role as a regulator of insulin signaling and leptin signaling, PTPN2 
has crucial functions in T cells as a modulator of inflammatory signaling and immune 
proliferation. Indeed, deletion of PTPN2 can lead to a cancer of T cells known as T cell 
acute lymphoblastic leukemia (T-ALL) due to unchecked immunoproliferation (Kleppe 
et al., 2010; Kleppe et al., 2011a). To assess the molecular function of PTPN2 in T cells, 
T cell specific Ptpn2 null mice were generated. In these mice, even with low-affinity 
antigens, PTPN2-deficient T cells show significant proliferation, and this lower threshold 
of activation and proliferation is mediated by enhanced TCR signaling. This leads to 
significant inflammation and autoimmunity in aged T cell Ptpn2 null mice, altogether 
suggesting that PTPN2 is indispensable for maintaining a threshold of activation and 
proliferation to preclude self-antigen recognition (Wiede et al., 2014; Wiede et al., 2011). 
Accordingly, human PTPN2 has been associated with a number of autoimmune disorders 
including T1D (Todd et al., 2007), Crohn’s and celiac disease (Festen et al., 2011), and 
rheumatoid arthritis (Wellcome Trust Case Control, 2007).  
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While it is clear that PTPN2 plays a role in suppressing inflammation, the fact 
that whole body Ptpn2 null mice experience much more pronounced systemic 
inflammation and earlier lethality than the T cell conditional null mice points to a 
compelling piece of evidence that PTPN2 in cell types other than T cells may contribute 
to suppress inflammation. It is possible that PTPN2 may function in other immune cell 
types such as dendritic cells or macrophages, but it is also likely that PTPN2 may 
modulate responses to the immune-mediated attack in cell types that are targeted for 
destruction, such as the pancreatic beta cells. 
 
Beta cell PTPN2 
As a T1D candidate gene, how PTPN2 affects beta cell survival upon apoptosis 
signaling has received considerable attention. It has been demonstrated that levels of 
PTPN2 were increased in human islets, primary rat beta cells and rat INS-1E cells upon 
treatment with cytokines IL-1β and IFN-γ or synthetic double stranded RNA, indicating 
that pro-inflammatory processes upregulate PTPN2. Furthermore, cytokine stimulation 
induced the redistribution of exclusively nuclear PTPN2 to become both nuclear and 
cytoplasmic, suggesting that nuclear exit of PTPN2 may be important upon death 
signaling (Colli et al., 2010; Moore et al., 2009).  
To assess the mechanism of PTPN2 in the beta cells, Ptpn2 was transiently 
inhibited in the INS-1E cells using small interfering RNAs (siRNAs) in the presence of 
cytokines and this resulted in an increased percentage of apoptotic cells and 
hyperphosphorylated STAT1 and STAT3. Double knockdown of PTPN2 and STAT1 
abolished this increase in apoptosis, supporting the notion that PTPN2 acts as a cytokine-
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responsive beta cell defense mechanism by dephosphorylating and deactivating STAT1 
(Moore et al., 2009). It remains unanswered whether the nucleocytoplasmic redistribution 
of PTPN2 works cooperatively or antagonistically with the beta cell defense mechanism.  
Another avenue in which PTPN2 regulates beta cell survival has shown to be   
through mitigating the mitochondrial pathway of apoptosis. Because silencing PTPN2 
heightened apoptosis signaling, Santin and colleagues examined the readouts of ER stress 
response and the mitochondrial death pathway. Genes induced by ER stress such as 
CHOP, immunoglobulin heavy chain-binding protein (Bip), and X-box binding protein 1 
spliced (Xbp-1s) were not changed in cytokine treated PTPN2 knockdown beta cells. In 
contrast, mitochondrial death pathway was significantly activated in beta cells with 
cytokine stimulation and PTPN2 inhibition, as demonstrated by focal translocation of 
BAX to the mitochondria, cytochrome c release to the cytoplasm, and activation of 
caspase 3. Activation of the intrinsic death pathway seems to be a result of the 
hyperactivation of C-Jun N-terminal kinase 1 (JNK1) in the absence of PTPN2 that leads 
to the hyperphosphorylation of the BH3-only pro-apoptotic protein BIM at serine 65, and 
the siRNA-mediated silencing of Jnk1 or Bim transcripts protected against cytokine-
induced apoptosis even in the absence of PTPN2 (Santin et al., 2011).  
Beta cell PTPN2 also participates in a crosstalk with another T1D candidate 
protein basic leucine zipper transcription factor (BACH2) to modulate apoptosis. In the 
study by Marroqui et al, BACH2 silencing also led to beta cell death via the 
hyperactivation of JNK1 and the mitochondrial pathway, and overexpressing BACH2 
was protective (Marroqui et al., 2014). BACH2-inhibited cells were unable to increase 
PTPN2 levels in response to pro-inflammatory cytokines, and the authors concluded that 
!
 25 
BACH2 is required to upregulate PTPN2 to ensure beta cell survival in response to 
apoptotic stimuli.  
Until recently, PTPN2 function in beta cell survival had only been shown in vitro. 
While cultured islets and beta cells are invaluable vehicles for studying the molecular 
mechanisms of diabetes, cell culture conditions may not recapitulate the complex in vivo 
environment of the pancreatic islets. Crucial growth factors and hormonal signals, as well 
as cytokines, may be missing, insufficient, or excessive, in the culture medium 
supplemented with fetal bovine serum. Moreover, stress-specific signaling may not be 
adequately modeled with the addition of cytokines in vitro. Therefore, it was necessary to 
model PTPN2 loss in beta cells in vivo by utilizing a genetic approach, which was the 
rationale behind my project design.  
As I was nearing the end of my project characterizing the in vivo requirement of 
beta cell PTPN2, two studies emerged to show that PTPN2 functions in pancreatic cell 
survival for both exocrine (Bettaieb et al., 2014) and endocrine cells (Xi et al., 2014) in 
vivo. These studies were conducted with whole-pancreas knockout model of PTPN2 
generated by crossing the Ptpn2-floxed mice with mice carrying the Cre allele driven by 
the Pdx1 promoter (referred to as panc-TCPTP KO in the papers). The panc-TCPTP KO 
mice had no gross phenotype and survived to adulthood. Upon treatment with the acinar 
cell toxin cerulein, in a chemical model of acute pancreatitis, PTPN2 was increased 
(Bettaieb et al., 2014). Cerulein treatment of panc-TCPTP KO mice led to a 
hyperactivation of STAT3 phosphorylation, amelioration of acinar cell apoptosis, and 
blunting of NF-κB inflammatory response, as well as ER stress, suggesting that PTPN2 
mediates apoptosis in acinar cells. This is in stark contrast to the in vitro beta cell model 
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of PTPN2 function in decreasing the cellular inflammatory response and apoptosis 
(Moore et al., 2009; Santin et al., 2011).  
The panc-TCPTP KO mice were also used to study the role of PTPN2 in beta 
cells (Xi et al., 2014). After the HFD challenge, the panc-TCPTP KO mice exhibited 
significant glucose intolerance and defects in glucose-stimulated insulin secretion (GSIS). 
This defect in GSIS was rescued in vitro by the reconstitution of PTPN2. The authors 
tested previously known substrates of PTPN2, STAT1 and STAT3, and concluded that 
STAT1 and STAT3 are bona fide dephosphorylation targets of beta cell PTPN2, and that 
panc-TCPTP KO mice have defects in beta function because of downstream effects of 
STAT3 hyperphosphorylation in the absence of PTPN2. In my study, I will show that 
beta cell PTPN2 is indeed critical for beta cell survival using an experimental model of 
murine beta cell loss in beta cell-specific knockout mice. Furthermore, I have discovered 
a novel mechanism of PTPN2-mediated beta cell survival, which may be relevant to 
T1D. 
 
Mediator of cell survival and death PKM2 
Overview 
Cell survival is highly dependent on obtaining energy stored in various nutrients. 
Energy generation involves the catabolism of nutrients such as glucose into units of 
energy known as adenosine triophosphate (ATP). During the process of glycolysis, 
intracellular glucose is converted to pyruvate in the cytoplasm, producing two molecules 
of ATP and reduced nicotinamide adenine dinucleotide (NADH). Then, depending on the 
availability of the electron accepting agent oxygen, 34 more ATP molecules can be 
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generated from breaking down pyruvate and oxidizing electron carriers such as NADH 
through mitochondrial reactions of citric acid cycle and oxidative phosphorylation. In the 
absence of oxygen, no further energy is generated, and pyruvate is converted into lactic 
acid, a cellular waste product that is readily shuttled out, during which NADH is 
converted to the oxidized form (NAD+) for reuse in subsequent glycolysis (Vander 
Heiden et al., 2009). Even with a relatively low yield (only two molecules of ATP), 
glycolysis is an important energy producing machinery, and the final step of glycolysis 
generates pyruvate and ATP, catalyzed by the enzyme pyruvate kinase (PK) (Fig. 1-6).  
Four isoforms of PK exist in mammalian cells encoded by two genes Pklr and 
Pkm. In the case of Pklr gene, tissue-specific promoters drive the expression of either the 
liver-type Pkl transcript (in liver, kidneys, and the intestine) or the red blood cell-type Pkr 
transcript (in red blood cells) (Noguchi et al., 1987). On the other hand, the muscle-type 
Pkm gene can produce two isoforms M1 and M2 by alternative splicing of exons 9 and 10 
(Clower et al., 2010; David et al., 2010; Noguchi et al., 1986). The M1 isoform is 
expressed in most differentiated tissues including brain and muscle, whereas the M2 
isoform is expressed in cell types with a high nutrient flux such as fetal cells and cancer 
cells (Christofk et al., 2008a; Netzker et al., 1992).  
 
Understanding the functions of PKM2 through cancer  
In cases of rapidly proliferating cells, high rate of nutrient uptake must be 
balanced by a comparable rate of utilization, and despite the lower yield of ATP, 
glycolysis is much more rapid than oxidative phosphorylation (Pfeiffer et al., 2001). 
Thus, the surplus of glucose is broken down by a high rate of glycolysis, which becomes 
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the primary method of energy production in cancer cells (DeBerardinis et al., 2008; 
Warburg, 1956). This shift toward an unusually high rate of glycolysis followed by lactic 
acid fermentation in cancer cells is known as the Warburg effect, and is accompanied by 
the preferential expression of the M2 isoform of PK. Compared to PKM1 expressing 
cells, PKM2 expressing cells consumed less oxygen, produced more lactate, and were not 
as sensitive to mitochondrial ATP synthase inhibitor oligomycin, all indicative of less 
oxidative phosphorylation in favor of glycolysis (Christofk et al., 2008a). Highlighted as 
the master regulator of cancer cell survival, PKM2 has received significant attention as 
the pharmacological target for cancer therapy (Mazurek, 2011).  
Selective pressure for PKM2 in highly glycolytic cells seems to be stemming 
from the versatility of PKM2 rather than the enzymatic activity per se, because the 
PKM2 enzymatic activity is in fact much lower than that of PKM1 due to structural 
differences. Differing by only 22 amino acids, PKM1 exists constitutively as a high-
activity tetramer, whereas PKM2 exists in equilibrium of low-activity forms of monomer, 
dimer, and T-state tetramer, as well as the high-activity R-state tetramer, which is 
dynamically regulated by structural changes caused by posttranslational modifications 
and allosteric binding of various intracellular metabolites (Morgan et al., 2013). In cancer 
cells, PKM2 exists primarily as the low-activity dimer, and the induction of high-activity 
tetramer configuration by the binding of upstream glycolytic intermediate fructose-1,6-
bisphosphate (FBP) can inhibit tumorigenesis (Anastasiou et al., 2012; Ashizawa et al., 
1991). FBP-mediated activation is inhibited by the phosphorylation of tyrosine residues 
in PKM2 that favors dimer conformation of PKM2 in cancer cells (Hitosugi et al., 2009; 
Presek et al., 1988). Furthermore, intracellular reactive oxygen species (ROS) 
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accumulation is characteristic of tumor growth (Ishikawa et al., 2008; Weinberg et al., 
2010), and ROS inhibits the active form of PKM2 by oxidation at cysteine 358, which is 
critical for cancer cell survival, as replacing this cysteine with oxidation resistant serine 
residue resulted in increased sensitivity to oxidative stress and decreased survival 
(Anastasiou et al., 2011). An idea that is gaining momentum in recent years is that PKM2 
may be important for cancer cell metabolism and survival because of physiological 
implications from its nonglycolytic functions. 
 
PKM2 as a regulator of transcription 
Many enzymes have evolved to be multifunctional, because functional plasticity 
could confer energy saving advantages to a cell (Jeffery, 1999). The earliest observation 
that PKM2 has nonglycolytic functions was in 2003, when Ignacak and colleagues 
discovered that nuclear PKM2 from hepatoma cells had histone H1 kinase activity 
(Ignacak and Stachurska, 2003). More recently, several major studies have shown that 
PKM2 can act as a protein kinase or a transcription factor cofactor to affect changes in 
gene expression.  
The role of PKM2 as a transcriptional regulator is dependent on its nuclear 
availability. Nuclear translocation of PKM2 can be induced with specific proliferative 
stimuli such as interleukin 3 (Hoshino et al., 2007), as well as apoptotic stimuli such as 
hydrogen peroxide (Stetak et al., 2007). Transcriptional differences between cells with 
nuclear PKM2 induced by proliferative or apoptotic stimuli have not been defined since 
PKM2 as a transcriptional regulator has been characterized primarily in the context of 
proliferative tumor cell types.  
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PKM2 has been shown to directly bind phosphorylated tyrosine residues 
(Christofk et al., 2008b), and nuclear PKM2 can regulate gene transcription through 
tyrosine kinase activity. Dimeric PKM2 can phosphorylate Y705 of STAT3 in the 
nucleus to activate proliferative genes such as mitogen-activated protein kinase kinase 5 
(Mek5) (Gao et al., 2012). Inhibiting tetramer formation by mutating the positive charge 
of R399 residue resulted in mostly dimeric PKM2 with higher protein kinase activity, and 
implanting the mutant PKM2-overexpressing cells into nude mice resulted in bigger and 
more proliferative tumor growth than the wildtype PKM2. Another study showed that 
EGF transactivates β-catenin through PKM2-mediated phosphorylation of β-catenin 
Y333 residue, culminating in the transcription of cyclin d1 (Ccnd1) and v-myc avian 
myelocytomatosis viral oncogene homolog (Myc) (Yang et al., 2011). Kinase activity of 
PKM2 may not be limited to tyrosine residues, as PKM2 can also phosphorylate 
threonine 11 of histone H3 to promote Ccnd1 and Myc gene transcription (Yang et al., 
2012a).  
PKM2-mediated transcription of certain genes may contribute to PKM2 
expression in a positive feedback mechanism. For instance, MYC upregulates the 
transcription of three heterogeneous nuclear ribonucleoproteins (hnRNP), protein 
products of which facilitate Pkm2 alternative splicing from the Pkm locus (Clower et al., 
2010; David et al., 2010). Furthermore, MYC may promote the Warburg effect by 
upregulating genes involved in glycolysis and lactate fermentation such as glucose 
transporter 1 (Glut1 or Slc2a1) and lactate dehydrogenase A (Ldha) (Osthus et al., 2000; 
Shim et al., 1997). Both Glut1 and Ldha belong to a class of genes whose transcription is 
controlled by the transcription factor hypoxia-inducible factor 1 alpha (HIF-1α) (Denko, 
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2008). In fact, PKM2 can directly activate HIF-1α target gene transcription by acting as a 
cofactor (Luo et al., 2011). Furthermore, Pkm gene bears an intronic hypoxia response 
element (HRE), which leads to HIF-1α-mediated upregulation of Pkm expression, which 
may compound the positive feedback loop of HIF-1α/PKM2 induced gene transcription 
(summarized in Fig. 1-7).  
 
PKM2 in beta cells 
In addition to proliferating cancer or fetal tissues, PKM2 is also expressed in 
pancreatic islets (Chatterton et al., 1982; MacDonald and Chang, 1985). Adult islet cells 
are not rapidly proliferating and it is unknown why PKM2 is favored over PKM1 in the 
islets. It is likely that rapid uptake of glucose is important for the function of glucose 
sensing and insulin release from the beta cells, which could result in nutrient excess, not 
unlike in cancer cells. However, whereas cancer metabolism has found a way to thrive 
with through PKM2, it is unknown whether ROS inhibits or activates PKM2 in islets. 
Furthermore, beta cells are much more susceptible to injury from increases in ROS 
compared to other cell types, and thus, in the context of islet beta cells, PKM2 may act to 
promote cell death as opposed to cell survival, with ROS acting as a metabolic switch.  
In my thesis work, I have addressed the function of PKM2 in beta cells that have 
been exposed to pro-apoptotic stimuli. I show that PKM2 interacts with T1D candidate 
PTPN2 in the beta cells, and that this interaction is critical for effective defense 
mechanism of the beta cells, as the beta cell-specific loss of PTPN2 results in exacerbated 
diabetes and beta cell loss. PKM2-mediated cell death mechanism appears to be through 
the transcriptional activation of pro-apoptotic transcripts that are regulated by HIF-
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1α/PKM2 complex, and facilitating the nuclear export of PKM2 using a small molecule 
activator attenuates the transcription of pro-apoptotic transcripts. Furthermore, I have 
discovered that in the NOD genetic background, beta cell Pkm2 levels may predispose 
the islets to insulitis-sensitivity or resistance. Thus, while investigating mechanisms of 
beta cell-intrinsic susceptibility to T1D, my studies have broadened the understanding of 
beta cell defense mechanisms and the therapeutic possibilities for T1D by implicating a 


















Figure 1-1. Natural history of T1D. 
A model of linear beta cell mass decay postulated by Eisenbarth in 1986. Figure adapted 










Figure 1-2. Histology of NOD islets at various stages. 
(A) Prediabetic islets at various stages: 5 wk (no infiltration), 10 wk (peri-insular 
insulitis), 20 wk (intra-insular insulitis up to 25% of islet mass), and 30 wk (intra-insular 
insulitis up to 75% of islet mass). Wk, age in weeks. Arrowheads indicate immune 
infiltrates. (B) End-stage insulitis with less than 20% of islet mass remaining. Figure 









Figure 1-3. Beta cell toxin streptozotocin. 
STZ is composed of glucose moiety (shaded in grey) attached to methylnitrosourea. 
Glucose residue facilitates beta cell specificity via uptake through GLUT2 glucose 
transporter. In the cell, methylnitrosourea residue alkylates and fragments DNA, leading 











Figure 1-4. Mammalian BCL-2 family proteins. 
BCL-2 family proteins with different BCL-2 homology (BH) domains are shown, 
categorized as pro-survival or pro-apoptotic. BH3-only proteins are pro-apoptotic BCL-2 







Figure 1-5. PTPN2 can exit the nucleus upon stimulation.  
(A) TC45 isoform of PTPN2 is mostly nuclear (green) in unstimulated COS1 cells (-
EGF). Upon epidermal growth factor stimulation for 15 minutes (+EGF), cytoplasmic 
and nuclear TC45 can be seen. Figure adapted from (Tiganis et al., 1998). (B) 
Fluorescence microscopy shows nuclear TC45 in unstimulated CHO/IR cells (-INS). 
After 30 minutes of insulin stimulation (+INS), non-nuclear TC45 can be seen. Figure 
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Figure 1-6. PKM2 generates pyruvate at the final step of glycolysis. 
Normally, PKM2 can exist as the high-activity tetramer or the low-activity dimer. During 
oncogenic processes, PKM2 can be modified by tyrosine kinase-mediated 
phosphorylation events that can inhibit the tetrameric form. Generally, the high-activity 
tetrameric form is associated with normal metabolic pathways including the tricarboxylic 
acid cycle and oxidative phosphorylation. The presence of low-activity dimeric PKM2 is 
associated with the Warburg effect, with a high rate of conversion of pyruvate to lactate. 
Figure from (Tamada et al., 2012). 
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Figure 1-7. Nonglycolytic functions of PKM2 in the nuclei of cancer cells. 
In the nucleus, PKM2 can transactivate HIF-1α, phosphorylate STAT3, and interact with 













Chapter Two: PTPN2 promotes beta cell survival by modulating PKM2-mediated 
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Protein tyrosine phosphatase N2 (PTPN2) is a type 1 diabetes candidate gene identified 
from human genome-wide association studies. PTPN2 is highly expressed in human and 
murine islets and is elevated upon inflammation, suggesting that beta cell PTPN2 may be 
important for cell survival. To test this in vivo, we generated beta cell-specific deletion in 
mice (Ptpn2 βKO). While unstressed animals exhibit normal metabolic profiles, 
streptozotocin (STZ) treated Ptpn2 βKO mice display marked increase in hyperglycemia 
and death due to exacerbated beta cell loss. Global transcriptome analysis revealed that 
beta cell function may also be impaired in the unstressed Ptpn2 βKO islets, which 
confirms the role of beta cell PTPN2 in the context of high fat diet-stressed animals. 
However, the known substrates of PTPN2 that are critical for beta cell function could not 
fully explain the mechanism of beta cell defense. Here we show that PTPN2 interacts 
with a novel substrate, pyruvate kinase M2 (PKM2), a key metabolic enzyme that 
normally resides in the cytosol. Adaptation to stress stimuli such as hypoxia leads to the 
nuclear translocation of PKM2 in many cell types, where it can act as a transcription 
factor. In beta cells, PKM2 migrates to the nucleus in response to STZ, where it activates 
the transcription of a subset of pro-apoptotic genes. In the absence of PTPN2, there is 
increased accumulation of PKM2 in the nucleus, which may account for exacerbated 
diabetes in Ptpn2 βKO mice. We have reconstituted the proposed function of PTPN2 by 
modulating nuclear PKM2 using TEPP46, a small molecule activator of PKM2 that 
stabilizes the cytosolic conformation of PKM2. Addition of TEPP46 to STZ-treated 
Ptpn2 βKO islets attenuated PKM2-mediated transcription of pro-apoptotic genes. These 
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findings suggest that PTPN2 is an important regulator of nuclear PKM2 in beta cells 





Autoimmune destruction of pancreatic beta cells by cytotoxic lymphocytes is the 
hallmark of type 1 diabetes (T1D). The initiation of insulitis leading to diabetes is 
multifactorial and has been attributed to both genetic and environmental factors (Todd, 
2010). Many of the genetic factors of T1D have been identified in the genome-wide 
association studies (GWAS) (Wellcome Trust Case Control, 2007), but the molecular 
mechanisms by which most risk alleles increase susceptibility to T1D remain unclear. It 
should be noted that over 60% of these GWAS candidate genes are strongly expressed in 
human islets (Eizirik et al., 2012), suggesting there are beta cell features that contribute to 
their destruction. In addition, compared to other cell types, beta cells express lower basal 
levels of antioxidant protective enzymes and therefore it has been hypothesized that they 
more sensitive to oxidative stressors (Lenzen et al., 1996). Together, this suggests that 
beta cell apoptosis in T1D susceptible individuals may be, at least in part, due to 
dysfunctional beta cell-intrinsic defense mechanisms to inflammatory stimuli. 
Protein tyrosine phosphatase N2 (PTPN2), also known as T-cell protein tyrosine 
phosphatase (TC-PTP), is a novel candidate gene for T1D (Todd et al., 2007). The 
association of PTPN2 with T1D risk remains incomplete, especially since PTPN2 is 
expressed in many tissue types, including T cells and pancreatic beta cells (Eizirik et al., 
2012). Risk variants of PTPN2 are noncoding (rs2542151, rs1893217, and rs478582), 
and one reported study correlates the risk variant rs1893217 to decreased expression of 
PTPN2 transcripts in T cells of T1D patients (Long et al., 2011). Disease modeling in 
mice through the conditional deletion of Ptpn2 in T cells has revealed that PTPN2 
negatively regulates immune signaling to temper inflammation (Wiede et al., 2011). Mice 
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lacking PTPN2 in T cells die of systemic inflammation, and the whole body Ptpn2 
knockout mice have more severe phenotypes and earlier lethality due to impairment in 
the bone marrow microenvironment critical for hematopoiesis (You-Ten et al., 1997). 
Unfortunately, due to the early lethality of the whole body Ptpn2 knockout mice, the 
function of PTPN2 in other cell types such as the pancreatic beta cells has been difficult. 
However, there is mounting evidence that PTPN2 is critical for beta cell survival, as in 
vitro PTPN2 knockdown in rodent and human primary beta cells exacerbates interferon-
induced apoptosis through signal transducer and activator of transcription 1 (STAT1) 
signaling (Moore et al., 2009; Santin et al., 2011). On the other hand, mice lacking 
PTPN2 in the pancreas (panc-TCPTP KO) are euglycemic and exhibit exacerbated 
glucose intolerance only after prolonged high fat feeding, which has been attributed to the 
hyperactivation of STAT3 (Xi et al., 2014).  
In this study, we report that conditional deletion of Ptpn2 in beta cells leads to 
exacerbated streptozotocin (STZ) induced diabetes due to the deregulation of pyruvate 
kinase M2 (PKM2)-mediated pro-apoptotic gene expression. Tetrameric pyruvate kinase 
plays a pivotal role in energy metabolism by catalyzing the final step of glycolysis, 
generating pyruvate and ATP. Non-tetrameric, low-activity PKM2 has been shown 
translocate to the nucleus to affect gene transcription by transactivating key transcription 
factors such as hypoxia-inducible factor 1 alpha (HIF-1α) and β-catenin or by acting as a 
kinase of transcription factors like STAT3 in cancer cells (Gao et al., 2012; Luo et al., 
2011; Yang et al., 2011). PKM2 is also highly expressed in islet beta cells (Chatterton et 
al., 1982; Martens et al., 2010), and we demonstrate that upon treatment with STZ, beta 
cell PKM2 translocates to the nucleus where it alters the transcription of HIF-1α-
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responsive genes. We also show that overexpressing a functional mutant of PTPN2 leads 
to an accumulation of nuclear PKM2 with STZ stress in beta cells, which suggests that 
the function of wildtype PTPN2 promotes the non-nuclear, and transcriptionally inactive, 
PKM2 tetramer. In the absence of such regulation in the conditional Ptpn2 beta cell 
knockout mice (Ptpn2 βKO), we observed a significant upregulation of HIF-1α/PKM2-
responsive genes, including pro-apoptotic transcripts Bnip3, Bnip3l, and Ddit4. 
Differences in the beta cell transcriptional landscape combined with poor tolerance of 
STZ treatment by the Ptpn2 βKO mice reveals a novel mechanism of PTPN2-mediated 
beta cell defense upon apoptotic stimuli. We demonstrate that PTPN2 modulates nuclear 
PKM2-mediated pro-apoptotic gene transcription, and exogenous modulation of nuclear 
PKM2 levels attenuates pro-apoptotic gene transcription. We conclude that PTPN2 is an 
essential beta cell factor that modulates cell survival upon injurious stimuli and illustrate 




Generation of the beta cell-specific PTPN2 knockout mice  
Given that PTPN2 knockdown exacerbates cytokine-induced apoptosis in vitro, 
we sought to test the beta cell requirement of PTPN2 in vivo by generating mice lacking 
PTPN2 in beta cells (Ptpn2fl/fl; RIP-Cre, henceforth, Ptpn2 βKO) (Herrera, 2000; Zee et 
al., 2012). In the Ptpn2 βKO mice, overall levels or Ptpn2 transcripts were unchanged, 
however ~81% of Ptpn2 transcripts had a deletion of the floxed exons in the Ptpn2 βKO 
islets. RNA-Seq analysis of the Ptpn2 βKO islets confirmed this finding (Fig. 2-1). 
!
 47 
Deletion of the floxed exons correlated with decreased PTPN2 protein expression in the 
Ptpn2 βKO islets, where PTPN2 was significantly decreased by 64%. PTPN2 expression 
was not changed in the hypothalamus, where ectopic RIP-Cre allele expression has been 
reported (Wicksteed et al., 2010) (Fig. 2-2).  
 
Characterization of the Ptpn2 βKO mice 
We hypothesized that PTPN2 would be required for beta cell survival and Ptpn2 
βKO mice would be diabetic. However, Ptpn2 βKO animals were born at the expected 
Mendelian ratios and were viable, fertile, and appeared healthy overall (Fig. 2-3A). In 10-
week-old animals, plasma glucose and insulin, glucose tolerance, insulin sensitivity, total 
insulin content, and islet morphology were comparable between Ptpn2 βKO and control 
littermates (Fig. 2-3B-E, 2-4). Ptpn2 βKO mice did not become spontaneously diabetic, 
even after aging for over 300 days (data not shown).  
To investigate molecular changes in the absence of diabetes, we isolated islets 
from adult Ptpn2 βKO and control mice and compared the global gene expression 
profiles through RNA-Seq. The analysis identified 1212 genes that are differentially 
expressed (Fig. 2-5A). Transcripts encoding insulin, Ins1 and Ins2, were comparably 
expressed but we observed decreased expression of a subset of beta cell transcription 
factors including Nkx2-2, Mafa, and FoxO1 (Fig. 2-5B).  
We then conducted pathway analysis and discovered that key canonical pathways 
such as toll-like receptor (TLR) and mammalian target of rapamycin (mTOR) signaling 
were affected (Fig. 2-5C). These signaling pathways have previously been implicated in 
beta cell survival or function (Fraenkel et al., 2008; Schulthess et al., 2009). Interestingly, 
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one of the upstream regulators contributing to the gene expression changes of the 1212 
genes was nuclear factor kappa B (NF-κB) (activation Z-score = 3.11), activation of 
which has been implicated in both the activation and prevention of beta cell apoptosis 
(Chang et al., 2003; Eldor et al., 2006). Furthermore, STAT3 was predicted to be highly 
activated upstream of the transcriptional changes in the Ptpn2 βKO islets (activation Z-
score = 3.12), and we have confirmed this finding (Fig. 2-6), which is consistent with 
reported hyperactivation of STAT3 in the panc-TCPTP KO islets (Xi et al., 2014). 
However, in the absence of overt phenotypic alterations in the adult animals, we decided 
to deliver exogenous metabolic stress to the Ptpn2 βKO and control mice. Unlike the 
panc-TCPTP KO mice, even after prolonged high fat feeding, Ptpn2 βKO mice did not 
display significant metabolic impairment or alterations in islet morphology compared to 
the control animals (Fig. 2-7), with the exception of one cohort of animals that exhibited 
differential weight gain due to unknown variables. 
 
Ptpn2 βKO mice develop exacerbated experimental diabetes  
In the absence of spontaneous or high fat-induced phenotypes, and considering 
the published in vitro function of PTPN2 in preventing beta cell apoptosis specifically in 
response to pro-inflammatory stimuli, we hypothesized that PTPN2 may become critical 
to beta cells facing apoptotic stimuli. Therefore, we administered multiple low-doses of 
streptozotocin (STZ) to chemically induce diabetes (Fig. 2-8). Differential ad lib 
hyperglycemia between Ptpn2 βKO and control animals were observed after two weeks 
(Fig. 2-8A), at which point glucose tolerance in Ptpn2 βKO and control animals were 
comparable. However, at week 3, we observed significantly exacerbated glucose 
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intolerance in addition to exacerbated hyperglycemia in the Ptpn2 βKO mice (Fig. 2-8C). 
To determine whether the hyperglycemia was due to differential beta cell loss, we 
examined the remaining islet cell populations using immunohistochemistry 4 months 
after STZ administration and determined that insulin-positive cells were less abundant in 
the Ptpn2 βKO islets (Fig. 2-9).  
Ptpn2 βKO mice develop exacerbated hyperglycemia and glucose intolerance 
from low-dose STZ stress, but due to the delayed onset of differences (several weeks) we 
could not eliminate the possibility of glucotoxic secondary effects caused by chronic 
hyperglycemia. To minimize any secondary effects, we wanted to analyze differential 
diabetes within a week of STZ administration. Since the one-week phenotype is very 
mild with low-dose STZ, we employed high-dose STZ treatment. A single high-dose of 
STZ was sufficient to induce significant diabetes in both mutant and control mice within 
two days of injection, but we were unable to assess any differences in hyperglycemia due 
to the upper limit of the glucometer measurements (<600 mg/dl) (Fig. 2-10A). However, 
underlying differences were indirectly revealed through significantly impaired survival of 
the Ptpn2 βKO mice compared to the controls, likely from the failure to maintain glucose 
homeostasis due to severe beta cell loss from STZ (Fig. 2-10B).  
We could not conclusively determine differential beta cell mass by 
immunohistochemistry because the high-dose STZ treatment obliterates most of the beta 
cells in the islets of both Ptpn2 βKO and control mice. Therefore, we assessed global 
transcriptomic changes in Ptpn2 βKO and control islets, which may be a more sensitive 
readout of differential beta cell survival or apoptosis. We identified 819 transcripts that 
were differentially expressed 5 days after high-dose STZ administration (Fig. 2-11, top 
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genes listed in Table 2-1). There was an overall trend of downregulation of beta cell 
transcripts in the Ptpn2 βKO islets, suggesting that perhaps the Ptpn2 βKO islets have 
fewer beta cells after STZ. Additionally, two genes involved in insulin secretion, piccolo 
(Pclo) and ATP-binding cassette transporter sub-family C member 8 (Abcc8) were 
significantly decreased, suggesting that there may be functional defects in the Ptpn2 βKO 
beta cells (Fig. 2-11B).  
Pathway analysis of differentially expressed transcripts yielded pathways of 
glucose metabolism, including tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation, suggesting glucose metabolism may be altered in the Ptpn2 βKO islets 
(Fig. 2-11C). Genes affecting mitochondrial function made up the number one most 
affected pathway of the RNA-Seq, which also affect glucose metabolism. In addition, 
mitochondrial function is key for cell survival and death (Green and Reed, 1998). We 
have successfully validated many of the gene expression changes involved in the 
mitochondrial dysfunction category using islets harvested at different time-points after 
STZ, and concluded that mitochondrial dysfunction is a persistent disease process after 
STZ (Fig. 2-11D). Interestingly, mTOR signaling was changed in both the unstressed and 
post-STZ RNA-Seq, which may indicate functional alterations in the Ptpn2 βKO islets. 
Furthermore, consolidation of the unstressed and post-STZ islet transcriptome data 
revealed that genes differentially expressed between the Ptpn2 βKO and control islets 
were involved in increased mitochondrial membrane permeability, as well as cell death 
and survival, suggesting that Ptpn2 βKO islets have basal functional alterations that are 




Beta cell PTPN2 interacts with PKM2 
Although it has been shown that PTPN2 inhibits the activation of transcription 
factor STAT3 in beta cells (Xi et al., 2014), we believe that STAT3 cannot account for all 
the transcriptional changes. For this reason, we sought to identify novel substrates of 
PTPN2. We transiently overexpressed epitope-tagged versions of wildtype and substrate-
trapping form of PTPN2 in murine beta cells. After subjecting the cells to stressful 
stimuli, we pulled down PTPN2 using the epitope tag and examined which proteins were 
associated with PTPN2 using mass spectrometry. We discovered that 48 proteins 
consistently interacted with PTPN2 (Table 2-2). The top pathways affected by these 
proteins included glycolysis, TCA cycle, and gluconeogenesis, which all affect glucose 
metabolism or de novo generation, drawing parallel with the pathways affected in the 
RNA-Seq (Fig. 2-13A). Additionally, many of the proteins in these pathways were 
positioned in the mitochondria, functioning in TCA cycle and oxidative phosphorylation 
(Fig. 2-13B), which also correlates with mitochondrial dysfunction in the Ptpn2 βKO 
islets identified from the RNA-Seq. Additionally, some of the most strongly identified 
proteins were endoplasmic reticulum (ER) resident proteins, such as 78 kDa glucose-
regulated protein (HSPA5, also known is BiP), transitional ER ATPase (VCP), and 
protein disulfide-isomerase A3 (PDIA3). Thus, mitochondrial and ER function could be 
affected by PTPN2 binding to these target proteins in the beta cells.  
One of the top five PTPN2-interacting proteins was pyruvate kinase M (PKM), an 
important glycolytic enzyme with posttranslational modifications including tyrosine 
phosphorylation. A recent study reported protein tyrosine phosphatase 1B (PTP1B) as a 
tyrosine phosphatase that regulates the M2 isoform of PKM (Bettaieb et al., 2013). Since 
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PTPN2 bears close resemblance to PTP1B (74% sequence identity in the catalytic 
domains) (Iversen et al., 2002), we hypothesized that PTPN2 might be a regulator of 
PKM2. The M1 and M2 isoforms are splice variants of the Pkm locus and differ by one 
exon encoding 55 amino acids, of which 22 are unique to either isoform (Fig. 2-14A). 
Mass spectrometry identified the M2 isoform-specific peptides with higher frequency 
(Fig. 2-14B) and Ptpn2 βKO and control islets express more Pkm2 transcripts than Pkm1 
(Fig. 2-14C). We concluded that Pkm2 is the major isoform in beta cells and focused 
further analysis on the relationship between PTPN2 and PKM2.  
We confirmed that PTPN2 interacts with PKM2 in vitro in Min6 cells and in vivo 
in mouse islets (Fig. 2-15). Unfortunately, our efforts to identify specific phosphotyrosine 
residue of PKM2 that is the substrate of PTPN2 through mutagenesis of known 
phosphotyrosine residues of PKM2 was inconclusive, possibly due to competition for 
PTPN2 interaction by high levels of endogenous PKM2. However, we have established 
that PTPN2 interacts with PKM2 in beta cells. 
 
PTPN2 modulates nuclear localization of PKM2 
Tyrosine 105 phosphorylation can inhibit the glycolytically active, cytoplasmic 
tetramer form of PKM2 (Hitosugi et al., 2009), and the dimeric form of PKM2 has been 
shown to be nuclear where it participates in transcription (Gao et al., 2012; Luo et al., 
2011). Therefore, we investigated the subcellular localization of PKM2 with confocal 
microscopy. In both Ptpn2 βKO and control islets from healthy animals, PKM2 was 
excluded from the nuclei, however, after STZ treatment, strong nuclear PKM2 signal 
could be observed (Fig. 2-16). It was difficult to determine differential nuclear 
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localization of PKM2 in Ptpn2 βKO and control islets using immunohistochemistry, 
however in vitro, there was decreased nuclear localization of PKM2 in STZ-treated Min6 
cells that overexpressed PTPN2 versus a mutant form of PTPN2 (Fig. 2-17). This 
suggests that the function of PTPN2 is critical for mitigating the accumulation of nuclear 
PKM2 in stressed beta cells, which is consistent with the hypothesis that diabetic Ptpn2 
βKO islets accumulate more PKM2 in the nuclei.  
 
PTPN2 regulates stress gene expression by modulating nuclear PKM2 
Nuclear PKM2 functions as a transcription factor and has been identified as a 
coactivator of hypoxia-inducible factor 1 alpha (HIF-1α)-mediated transcriptional 
changes that promote cancer cell metabolism (Luo et al., 2011). Because HIF-1α is 
activated in response to reduced oxygen tension (Semenza, 2013) and because 
mitochondrial function is highly dependent on the availability of oxygen, we 
hypothesized that the transcriptional differences relating to increased mitochondrial 
dysfunction in the Ptpn2 βKO islets may be related to the cellular oxygen sensing 
machinery regulated by the PTPN2-PKM2 interaction. In fact, a HIF-1α target, Egl-9 
family hypoxia-inducible factor 3 (Egln3), was upregulated by 65-fold in the Ptpn2 βKO 
islets. Furthermore, pathway analysis identified HIF-1α as one of the most activated 
upstream regulators of differentially expressed genes (activation Z-score = 3.21), which 
comprised of the 19 transcripts listed in Table 2-3. Direct expression analysis of known 
HIF-1α target genes (Benita et al., 2009; Liu et al., 2012) in the Ptpn2 βKO and control 
islets identified the upregulation of additional HIF-1α/PKM2-regulated genes (Fig. 2-18). 
Three of the upregulated HIF-1α/PKM2 target genes included key stress-response genes 
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such as BCL-2/adenovirus E1B 19kDa-interacting protein 3 (Bnip3), Bnip3-like (Bnip3l), 
and DNA damage-inducible transcript 4 (Ddit4). Bnip3 and Bnip3l encode pro-apoptotic 
proteins of the BNIP3 subfamily of the BH3-only proteins that localize to the 
mitochondria and induce cell death by interacting with pro-apoptotic proteins like BCL-
2-antagonist/killer 1 (BAK) and BCL-2-associated X protein (BAX) and by inhibiting 
pro-survival proteins such as B-cell CLL/lymphoma 2 (BCL-2) (Chinnadurai et al., 2008; 
Czabotar et al., 2014; Lomonosova and Chinnadurai, 2008). Aside from Bnip3 and 
Bnip3l, the transcript levels of Bak, Bax, Bcl2, and other BCL-2 family genes involved in 
apoptosis were expressed at comparable levels between Ptpn2 βKO and control islets 
(Table 2-4). Collectively, T1D-conducive pro-apoptotic beta cells upregulate HIF-
1α/PKM2 target genes, and the degree of upregulation may be modulated by the presence 
of PTPN2. 
 
Exogenous reconstitution of PTPN2 function rescues transcriptional alterations  
To directly assess whether PTPN2 modulates nuclear PKM2-mediated 
transcription of target genes, we sought to reconstitute the nuclear exclusion of PKM2 in 
PTPN2-deficient beta cells. Small molecule activators of PKM2 such as TEPP46 activate 
the tetrameric form of PKM2 that is cytosolic (Anastasiou et al., 2012). If PTPN2 
functions to lessen nuclear PKM2 in stress conditions, adding TEPP46 could compensate 
for the loss of PTPN2-mediated nuclear export of PKM2 by activating the cytosolic form 
of PKM2. We therefore stressed the Ptpn2 βKO islets with STZ in the presence or 
absence of TEPP46 (Fig. 2-19A). Remarkably, upregulation of HIF-1α/PKM2-responsive 
genes with STZ was effectively diminished by the depletion of non-tetrameric nuclear 
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PKM2 by TEPP46 (Fig. 2-19B). Although HIF-1α/PKM2 target genes were still 
significantly upregulated compared to islets not subjected to STZ stress, the degree of 
upregulation was milder than islets treated with STZ alone. This suggests that PTPN2 
lowers nuclear levels of PKM2 in the beta cells to attenuate the transcription of pro-





Summary of the findings 
In the present study, we demonstrated that PTPN2 is required in beta cells; Ptpn2 
βKO mice that lack functional beta cell PTPN2 experience impaired survival in the face 
of the diabetic stressor STZ. We have identified PKM2 as a PTPN2-interacting protein. 
PKM2 translocates to the nucleus following STZ injection, where it mediates HIF-
1α/PKM2-responsive gene transcription, including the key pro-apoptotic genes Bnip3 and 
Bnip3l. PTPN2 is required to modulate the expression of Bnip3 and Bnip3l, as well as 
other HIF-1α/PKM2-responsive genes by modulating the accumulation of PKM2 in the 
nuclei of stressed beta cells. Reconstituting this function of PTPN2 in Ptpn2 βKO islets 
by activating non-nuclear PKM2 decreases the transcriptional activation of HIF-
1α/PKM2-responsive genes. This study is the first to identify transcriptional changes 
induced by PKM2 in a non-cancerous cell type and may have broadened therapeutic 




Comparison with the panc-TCPTP KO phenotype 
A recent study of PTPN2 requirement in pancreatic endocrine cell function (Xi et 
al., 2014) was conducted with a whole-pancreas knockout model of PTPN2 (referred to 
as panc-TCPTP KO). Consistent with the panc-TCPTP KO mice, the Ptpn2 βKO animals 
also had no gross metabolic phenotype and survived to adulthood. After HFD challenge, 
however, the panc-TCPTP KO mice exhibited significant glucose intolerance and defects 
in beta cell function, whereas the Ptpn2 βKO animals did not. Several differences in the 
study designs could account for this discrepancy. First, the panc-TCPTP KO mice were 
maintained in the C57BL/6J background, and the authors note the possibility that their 
phenotype of reduced insulin secretion may have been due to the deletion of nicotinamide 
nucleotide transhydrogenase (Nnt) in the genetic background (Xi et al., 2014). In our 
study, Ptpn2 βKO animals were maintained in a mixed background. Second, the panc-
TCPTP KO mice were switched to HFD soon after weaning, whereas the Ptpn2 βKO 
mice were given HFD after reaching adulthood (10 weeks). It is possible that there may 
be an early time window during which adaptation to diet-induced obesity may be 
critically influenced by PTPN2. Furthermore, the panc-TCPTP KO study mentions that 
even in the control mice, PTPN2 expression in the pancreas significantly decreased after 
HFD, suggesting that differences in panc-TCPTP KO and control mice after HFD may be 
due to subtle differences in PTPN2 levels.  
The panc-TCPTP KO study demonstrated that knocking down PTPN2 in beta 
cells in vitro led to a significant reduction of important factors influencing beta cell 
function, including Glut2, Pdx1, Ins1, Ins2, and Kir6.2 (Xi et al., 2014). Consistent with 
this finding, we show that deletion of PTPN2 leads to an overall trend of downregulation 
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of key transcription factors in beta cells, including Pdx1, Nkx2-2, Nkx6-1, Foxo1, Mafa, 
and Isl1, which supports the idea that PTPN2 is required for the proper function of beta 
cells (Fig. 2-5). However, unlike the in vitro analysis, we did not detect a substantial 
decrease in Ins1, Ins2, and Kir6.2 also known as Kcnj11, which encodes a pancreatic 
ATP-sensitive potassium channel subunit critical for insulin secretion. This may be due 
to differences between acute and chronic loss of PTPN2, and our in vivo results may be 
more consistent with the observed normal metabolic phenotypes in our Ptpn2 βKO and 
their panc-TCPTP KO mice without exogenous stress.  
 
The mechanism of PTPN2-mediated STAT3 regulation in beta cells 
The panc-TCPTP KO study identified previously known substrates of PTPN2, 
namely STAT1 and STAT3, as bona fide dephosphorylation targets of PTPN2 in beta 
cells, and defective beta cell function in the panc-TCPTP KO mice was attributed to the 
hyperactivation of STAT3. Beta cell function was restored by the inhibition of STAT3 in 
PTPN2-deficient beta cells (Xi et al., 2014). However, because STAT3 hyperactivation 
has been shown to be protective against NF-κB inflammatory response and apoptosis in 
other cell types (Bettaieb et al., 2014), it could not fully account for the changes we 
observed in STZ-induced beta cell loss. Furthermore, knockout mouse studies aimed at 
identifying the role of STAT3 in the beta cells have yielded conflicting results.  
Beta cell-specific STAT3 knockout mice have defects in insulin secretion and 
islet architecture, accumulating alpha cells in the center of islets instead of in the 
periphery (Cui et al., 2004; Gorogawa et al., 2004). In addition, beta cell STAT3 
knockout mice display increased obesity, partly because of STAT3 deletion in the 
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hypothalamic neurons due to the ectopic expression of RIP-Cre. To differentiate beta 
cell-specific requirement of STAT3 in the absence of STAT3 deletion in the 
hypothalamus, two groups generated pancreas-specific STAT3 knockout mice. In one 
study, mice with pancreas knockout of STAT3 did not develop obesity or glucose 
intolerance, and the islet architecture was surprisingly normal, leading to the conclusion 
that STAT3 is dispensable for beta cell development and function (Lee and 
Hennighausen, 2005). In another study, the knockout mice exhibited impairment in beta 
cell function and significant glucose intolerance, which was attributed to the 
disorganization of the islet vascular development (Kostromina et al., 2010). Thus, 
because the lack of STAT3 was associated with impaired beta cell function in several 
studies, STAT3 hyperactivation cannot fully explain the observed beta cell dysfunction in 
panc-TCPTP KO islets after high fat diet or exacerbated beta cell loss in the Ptpn2 βKO 
islets after STZ treatment. It is possible that this is due to differences in complete loss of 
STAT3 as opposed to the chronic activation of STAT3.  
STAT3 activation in other cell types is controlled by various factors such as the 
suppressor of cytokine signaling 3 (SOCS3) (Yoshimura et al., 2007). It should be noted 
that Socs3 was one of the most significantly upregulated transcripts in the unstressed 
Ptpn2 βKO islets (DESEQ P = 1.03E-07), even though STAT3 was hyperphosphorylated 
by immunoblotting in the Ptpn2 βKO islets, suggesting that without the chronic stress of 
high fat diet, the mice are able to maintain sub-threshold levels of STAT3 activation 
through regulatory mechanisms such as Socs3. Therefore, we sought to identify other 
substrates of PTPN2 in in Ptpn2 βKO islets that may be responsible for compromised 
beta cell defense. 
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mTOR hyperactivation in PTPN2-deficient beta cells  
Our transcriptome analysis from both unstressed and STZ-stressed islets 
identified mammalian target of rapamycin (mTOR) signaling as being upregulated in the 
Ptpn2 βKO islets. Because mTOR is a serine/threonine kinase, mTOR signaling is more 
often assessed by the changes in phosphorylation cascades, but the transcriptional 
upregulation of key mTOR activators such as ras homolog enriched in brain (Rheb) 
suggest that mTOR signaling is affected in the Ptpn2 βKO islets, especially after STZ.  
mTOR is a nutrient sensor that promotes protein translation and cellular growth 
(Wullschleger et al., 2006). mTOR exists as two complexes: rapamycin-sensitive 
complex mTORC1 with the regulatory-associated protein of mTOR (RAPTOR) and 
rapamycin-resistant mTORC2 with rapamycin-insensitive companion of mTOR 
(RICTOR) (Loewith et al., 2002). mTORC1 has been shown to induce the 
phosphorylation of ribosomal S6 kinase 1 (S6K1) to regulate IRS2 turnover (Shah et al., 
2004). IRS2 is critical for beta cell survival, and its depletion by mTOR-mediated 
phosphorylation can lead to beta cell apoptosis, which can be prevented by mTOR-
inhibition with rapamycin (Briaud et al., 2005; Hennige et al., 2003; Lingohr et al., 
2002). Rapamycin-mediated inhibition of mTOR can also inhibit beta cell proliferation, 
suggesting that mTOR signaling functions in both apoptosis and proliferation in the beta 
cells (Liu et al., 2009). Hyperactivating mTOR by overexpressing the upstream activator 
of mTOR, RHEB, in the beta cells, leads to increased beta cell function and mass, as well 
as resistance to STZ-induced diabetes (Hamada et al., 2009). However, in the diabetes-
prone NOD strain, beta cell-specific hyperactivation of mTOR through RHEB 
overexpression results in accelerated diabetes, and the authors conclude that the 
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enlargement of beta cells may in fact enhance the autoimmunity (Sasaki et al., 2011). 
This could also be due to increased apoptosis signaling by mTOR. The upregulation of 
Rheb transcript in the Ptpn2 βKO islets after STZ could also indicate similar increases in 
apoptosis, as we did not observe a significant increase in beta cell size in the Ptpn2 βKO 
islets. To date, the relationship between PTPN2 and mTOR is unstudied, and further 
investigation into whether and how PTPN2 regulates mTOR signaling may be 
illuminating for the understanding of beta cell loss in diabetes.  
 
The role of PTPN2 in preventing the nuclear accumulation of PKM2  
The novel finding in this study is that beta cells deficient in functional PTPN2 
have a higher level of nuclear PKM2, positively regulating HIF-1α/PKM2-mediated 
transcription. Our model is that PTPN2 mediates nuclear-to-cytoplasmic translocation of 
PKM2, counteracting stressful stimuli that drive the nuclear localization of PKM2 (Fig. 
2-20B). The most likely scenario is that PTPN2 dephosphorylates phosphotyrosine 
residues of PKM2 that inhibit the cytosolic tetramer conformation, such as the Y105 
residue (Hitosugi et al., 2009). It should be noted that phosphotyrosine binding to the 
catalytic domain of PTP is transient, and classical studies of substrate identification of 
protein tyrosine phosphatases (PTPs) are conducted with substrate trapping mutants 
(Blanchetot et al., 2005). For instance, substrate trapping mutant of PTP1B, the only 
known phosphatase of PKM2 and a closely related tyrosine phosphatase family protein of 
PTPN2, is unable to bind Y105F mutant of PKM2 because PTP1B directly 
dephosphorylates the Y105 residue (Bettaieb et al., 2013). Curiously, in our study, we did 
not observe any significant differences in PKM2 binding affinity in wildtype and 
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substrate trapping mutant PTPN2 in both mass spectrometry and validation 
immunoblotting (Fig. 2-15, Table 2-2). Further study will be needed to determine 
whether PKM2 is a direct dephosphorylation target of PTPN2.  
Our study has shown that loss of PTPN2 accumulates PKM2 in the beta cell 
nuclei, but we cannot rule out the possibility that PTPN2 mediates the nuclear export of 
PKM2 in a method other than direct dephosphorylation of PKM2. If PTPN2 binding to 
PKM2 is not specific to the catalytic domain, PTPN2 could mediate nuclear export of 
PKM2 by the physical translocation of the PTPN2-PKM2 complex upon death-inducing 
stimuli. Another uncertainty is whether the interaction of PTPN2 with PKM2 is specific 
to PKM2 conformation. It is possible that PTPN2 binds more strongly to the tetrameric 
PKM2 in the cytoplasm, in effect stabilizing the cytosolic PKM2, favoring the equilibrial 
shift of dimer to tetramer PKM2. Structural analysis of PTPN2-PKM2 complex is needed 
to determine whether PTPN2 binds more strongly to a particular PKM2 conformation. 
Although we cannot rule out other mechanisms of PTPN2-mediated PKM2 nuclear 
export, we observe significant transcriptional deregulation of HIF-1α/PKM2-responsive 
pro-apoptotic genes in the Ptpn2 βKO islets, suggesting that PTPN2 is critical for 
preventing PKM2 accumulation in the nucleus. 
 
The ramifications of nuclear accumulation of PKM2 in diabetic islets, and evidence 
for increased apoptosis signaling in the Ptpn2 βKO islets 
Most of the studies of nontraditional role of PKM2 as a transcription factor focus 
on PKM2 as a mediator of cell proliferation or survival in Warburg effect of cancer cells 
(Gao et al., 2012; Luo et al., 2011; Wang et al., 2014; Yang et al., 2011; Yang et al., 
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2012b). Warburg effect is a phenomenon of increased ratio of glycolysis to oxidative 
phosphorylation, shuttling pyruvate away from oxidative phosphorylation in favor of 
lactate production (DeBerardinis et al., 2008; Warburg, 1956), which occurs in rapidly 
proliferating fetal tissues or tumors that must adapt to decreased oxygen tension and 
surplus of growth factors such as epidermal growth factor (EGF). Hypoxia within the 
tumor tissue and the activation of HIF-1α is well documented in cancers, and it has been 
posited that HIF-1α/PKM2-mediated transcriptional regulation in tumor cells allows for 
metabolic reprogramming required for cell proliferation and cancer progression (Luo et 
al., 2011; Yang et al., 2011). HIF-1α-induced genes facilitate the Warburg effect, but 
even in the context of hypoxic tumor cells, HIF-1α activation is highly cell type- and 
context-dependent, as it can also promote apoptosis, and HIF-1α-null tumors show 
accelerated growth owing to decreased HIF-1α-mediated apoptosis (Carmeliet et al., 
1998). This dual role as a survival and apoptotic agent may also be at the heart of beta 
cell survival and apoptosis, with PKM2 acting as a regulatory switch.  
In somatic cell types, only one report demonstrates HIF-1α/PKM2-mediated 
transcriptional changes. Inflammation and sepsis induced by lipopolysaccharides can 
change macrophage metabolism to that similar to Warburg effect, which further activates 
macrophages and stimulates the release of pro-inflammatory cytokines (Everts et al., 
2012; Tannahill et al., 2013). A recent study in macrophages has shown that HIF-
1α/PKM2-mediated transcription is at the heart of macrophage activation and inhibiting 
PKM2 protected mice from endotoxin-induced septic death by modulating macrophage 
activation (Yang et al., 2014). However, inflammation and immune activation involves 
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immune cell proliferation. Hence, there is scant evidence of PKM2-induced 
transcriptional changes in nonproliferating cell types. 
With mounting evidence that PKM2 is a pro-survival protein in proliferating cells, 
the only instance of nuclear PKM2 inducing cell death was in 2007, when Stetak et al 
reported nuclear translocation of PKM2 in response to several pro-apoptotic stimuli. 
They reported cell death activation after PKM2 nuclear translocation, but did not 
investigate the function of PKM2 as a transcription factor in the nuclei of apoptotic cells 
(Stetak et al., 2007). This is what we have addressed in this study, by looking globally at 
the transcriptional landscape of beta cells after apoptosis-inducing stimuli, with or 
without PTPN2 which regulates nuclear PKM2.  
Evidence of PKM2 in cell proliferation and apoptosis suggests a dual function of 
nuclear PKM2 – pro-survival adaptive response in cells exposed to low oxygen tension or 
aberrantly increased growth factors and pro-apoptotic response in cells that are by default 
more prone to damage, such as the pancreatic beta cells as evidenced by inherently low 
levels of antioxidant defense mechanism (Carlsson et al., 1998). Dual function of nuclear 
PKM2 may be indirectly observed from the physiological consequences of HIF-
1α/PKM2 target genes. For example, Ddit4 was significantly upregulated in an animal 
model of ischemic injury, and the overexpression of Ddit4 protected breast cancer cells 
from hypoxia and hydrogen peroxide-induced cell death, but in non-dividing cell types, 
the overexpression of Ddit4 led to increased sensitivity to cell death (Shoshani et al., 
2002). Two other HIF-1α/PKM2 target genes are pro-apoptotic transcripts Bnip3 and 
Bnip3l that are upregulated in the Ptpn2 βKO islets, and these genes may coordinately 
generate a pro-apoptotic environment by interacting with BCL-2 family proteins, which 
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were not transcriptionally activated. There may be posttranslational modifications of 
BCL-2 family proteins that are undetected by the RNA-Seq, but the fact that only these 
pro-apoptotic BCL-2 family proteins were upregulated at the transcriptional level 
highlights the shift towards apoptosis. Furthermore, in vitro studies of PTPN2 
knockdown have established that another pro-apoptotic BCL-2 family protein, BIM, is 
activated by phosphorylation (Moore et al., 2009; Santin et al., 2011) supports our 
finding that the balance of cell survival to cell death is shifted to be more pro-apoptotic in 
the absence of PTPN2. Additional differentially expressed transcripts support the pro-
apoptotic environment of Ptpn2 βKO islets. In Table 2-1, top six of the most upregulated 
transcripts – Cyp2b10, Cidea, Egln3, Hamp, Ppbp, and Il22ra2 – and two of the 
transcripts only expressed in the Ptpn2 βKO islets after STZ – Cxcl13 and Il31ra – have 
all been reported to be upregulated in inflammation or apoptosis (Feld et al., 2010; 
Gnana-Prakasam et al., 2008; Gonzalez-Cortes et al., 2012; Inohara et al., 1998; 
Lomonosova and Chinnadurai, 2008; Saez de Guinoa et al., 2011; Wei et al., 2000).  
Another highly expressed transcript in the STZ-treated Ptpn2 βKO islets was p53-
induced protein 1 (Trp53inp1), induction of which is associated with increased apoptosis 
in beta cells (Okamura et al., 2001; Zhou et al., 2012). It has been shown that expression 
of Trp53inp1 is controlled by a microRNA cluster known as maternally expressed 3 
(Meg3), which encodes several alternatively spliced non-coding RNAs (Kameswaran et 
al., 2014). Furthermore, in islets from T2D patients showed a decrease in Meg3 
expression and an increase in the target Trp53inp1 mRNA levels, which the authors 
attribute to increased apoptosis signaling in the T2D islets. We also observed a significant 
decrease in Meg3 transcript in the STZ-diabetic Ptpn2 βKO islets (DESEQ P = 0.00017), 
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as well as decreases in several other transcripts in the cluster (Rian, Mirg, Rtl1, and 
Begain), and together with the induction of Trp53inp1 and HIF-1α/PKM2-activated stress 
genes may be a reliable indication of increased apoptosis signaling in the Ptpn2 βKO 
islets after STZ.  
 
HIF-1α in beta cells 
In addition to lower antioxidant enzyme expression, pancreatic islets may be more 
susceptible to damage because of lower native oxygen tension (Carlsson et al., 1998),  
which can activate or stabilize HIF-1α protein in the islets. Indeed, genetic stabilization 
of HIF-1α in the beta cells through the deletion of HIF-1α degradation protein von 
Hippel-Lindau (VHL) leads to impaired beta cell function, which can be rescued by the 
concomitant deletion of HIF-1α in the beta cells (Cantley et al., 2009; Puri et al., 2009; 
Zehetner et al., 2008). Mice with beta cell-specific HIF-1α deletion showed normal 
glucose homeostasis and slightly improved beta cell function in mixed genetic 
background (Cantley et al., 2009), but after 12 rounds of backcrossing into the C57BL/6J 
genetic background, beta cell HIF-1α-null mice exhibited significant impairment in 
glucose tolerance coupled with beta cell dysfunction (Cheng et al., 2010). The authors 
hint that subtle changes in HIF-1α dosage in different genetic backgrounds may account 
for such conflicting results. However, it is possible that such variable results may be 
linked to the dual function of HIF-1α in cell proliferation and apoptosis in response to 
altered oxygenation in the islets. 
Normal beta cell function is dependent on mitochondrial oxidative 
phosphorylation, which may be why islets normally suppress glycolytic genes such as 
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Ldha (Sekine et al., 1994). Recently, Warburg-like effect of increased lactate production 
was observed in the islets of non-obese model of rat T2D (Sasaki et al., 2013). This was 
attributed to increased ROS, and treatment with an antioxidant mimetic to reduce ROS 
countered this effect by decreasing HIF-1α protein. However, despite the fact that HIF-1α 
is a well-studied transcription factor, this study does not characterize any transcriptional 
changes due to HIF-1α in diabetic islets. Furthermore, beta cell ROS also plays a 
significant role in T1D, and it is unknown whether this Warburg-like effect accompanies 
or even contributes directly to beta cell loss in T1D. It remains to be seen whether STZ-
stressed beta cells also have this Warburg-like effect, but the upregulation of Ldha and 
other HIF-1α/PKM2-activated genes suggest that it is possible.  
 
PTPN2 and cellular defense 
PTPN2 has been previously implicated in other autoimmune diseases such as 
Crohn’s disease, ulcerative colitis, and celiac disease (Festen et al., 2011; Glas et al., 
2012). This is understandable since PTPN2 is required for the immunomodulation in T 
cells (Wiede et al., 2011). However, PTPN2 is also important in cells targeted by the 
immune system; Penrose et al used an activator of PTPN2, spermidine, on intestinal cells 
and found that they were protected from interferon γ (IFN-γ) induced mucosal barrier 
damage (Penrose et al., 2013). Together with our study, this suggests that PTPN2 may 
play a role in self-defense machinery in cell types that are targeted for destruction. It will 
be informative to obtain T1D patient tissues to conduct tandem DNA array and RNA-
Seq, to examine the effect of any diabetes-associated PTPN2 SNPs on the expression of 
PTPN2 in diabetic beta cells. This approach will also establish whether PTPN2 SNPs 
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correlate with the expression of PKM2-induced pro-apoptotic genes, and further, with 
disease onset or progression.  
Our study demonstrates that PTPN2 controls beta cell survival by modulating 
PKM2-mediated transcription of apoptosis-inducing genes such as Bnip3 and Bnip3l. 
This finding could be studied to prevent T1D and serve to understand other PTPN2-
mediated disease processes such as ulcerative colitis. Lastly, this work could further 
differentiate pro-apoptotic or pro-survival effect of HIF-1α/PKM2-mediated 
transcriptional activation, which will be useful for optimizing cancer therapeutics and 
open a potential for preventing diabetes in susceptible individuals.  
 
Materials and Methods 
 
Mouse studies. All mice were maintained on a mixed strain background of C57BL/6J 
and 129/Sv (Jackson). Ptpn2-floxed mice harboring loxP sites flanking exons 5 and 7 of 
the Ptpn2 gene (Zee et al., 2012) were crossed with mice expressing Cre under the 
control of rat insulin-2 promoter (RIP-Cre) (Herrera, 2000) to generate beta cell-specific 
PTPN2 knockout mice (Ptpn2 βKO). Littermates heterozygous for the Ptpn2-floxed 
allele with the Cre and littermates homozygous for the Ptpn2-floxed allele without the 
Cre were used as controls. Genotyping was performed by PCR using tail DNA as 
described previously (Herrera, 2000; Zee et al., 2012). For high fat feeding, mice were 
switched to a high fat diet at 10 weeks of age (60% kcal fat, D12492i, Research Diets). 
For high-dose STZ treatment, Ptpn2 βKO and littermate controls were fasted for 4 hours 
(h) and injected intraperitoneally (i.p.) with 150 mg STZ (Sigma) per kg body weight, 
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freshly dissolved in 0.1 M sodium citrate buffer (pH 4.5). All injections were done within 
10 minutes of STZ solution preparation. Hyperglycemia and body weight were monitored 
every 2- to 3-days, and mice were monitored for survival for two weeks or euthanized at 
days 5 or 8 post STZ injection to harvest tissues. For multiple low-dose STZ treatment, 
mice were fasted for 4 h and injected i.p. with 50 mg STZ per kg body weight on five 
consecutive days. Only male mice 4- to 6-week-old were used for the STZ experiments. 
All mice were maintained on a 12-hour light/dark cycle in a barrier facility with standard 
chow. All animal studies were approved by the Institutional Animal Care and Use 
Committee at the Columbia University Medical Center. 
 
Islet isolation and culture. Pancreatic islets were isolated from mice following a 
modified version of published protocol (Gotoh et al., 1985). Briefly, after the digestion of 
the exocrine tissue with Collagenase P (Roche), remaining tissues were separated by 
density gradient centrifugation using Histopaque-1077 (Sigma). After handpicking under 
a microscope, islets were flash-frozen and stored at -80 °C until processing, or cultured in 
RPMI supplemented with 10% FBS (Gemini) and 1x antibiotic-antimycotic (Fisher). 
Prior to the ex vivo STZ treatment, islets were allowed to recover from stressful islet 
isolation procedure. After 24 h recovery, islets were seeded 50 islets per well to 6-well 
plates, and islets were pretreated for 24 h with 26 µM per well of TEPP46 (Millipore) 
dissolved in DMSO, well beyond 300-fold over the AC50 of 92 nM, or equal volumes of 
DMSO for the controls. Islets were then subjected to 24 h of 1 mM STZ or buffer with or 
without TEPP46. STZ was used at 1 mM per well from 200 mM STZ solution, prepared 
immediately before treatment.  
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Metabolic assays. Ad lib or fasting (overnight) blood glucose and serum insulin were 
measured from tail vein blood using a glucometer (Accu-Chek) and a mouse insulin 
ELISA kit (Mercodia). For the glucose tolerance test (GTT), mice were fasted for 12-18 h 
overnight and a single i.p. glucose bolus of 2 g D-glucose (Sigma) per kg body weight 
was injected at time zero. Blood glucose was measured before and at times 15, 30, 60, 90, 
120 min after glucose administration. For the insulin tolerance test (ITT), mice were 
fasted 4-6 h during the day and injected with 1 U recombinant human insulin (Humulin 
N, Eli Lilly) per kg body weight. Blood glucose was measured and was analyzed by 
calculating percent initial blood glucose of each post insulin administration time points. 
 
Cell culture and plasmids. Mouse insulinoma Min6 cells were cultured in complete 
DMEM 4.5 g/L glucose (Fisher), 15% FBS (Gemini), 1x antibiotic-antimycotic (Fisher). 
Cells were transiently transfected using DMEM and Lipofectamine 3000 (Invitrogen) 
according to the manufacturer’s instructions. For mass spectrometry, Min6 cells were 
transfected with pCMV5-huPTPN2-Flag (WT or DA) or control pCMV5-Flag plasmids 
for 48 h, and cells were exposed to low glucose and serum-starvation (1 g/L glucose, 
<2% FBS) conditions for 2 h to optimize phosphorylated tyrosine substrates for the 
PTPN2 bait protein. Tyrosine phosphorylation after different stress conditions were 
optimized prior to the mass spectrometry through immunoblotting with anti-
phosphotyrosine antibody (4G10 Platinum, Millipore). Flag-tagged Pkm2 construct was 
generated by molecular cloning into pCMV5-Flag, and tyrosine residues of PKM2-FLAG 




RNA analysis. Total RNA was extracted using either the RNeasy Micro or Mini Kit 
(Qiagen) along with RNase-free DNase set (Qiagen), and cDNA was prepared using the 
SuperScript III First Strand Synthesis System (Invitrogen). Real time quantitative PCR 
(RT-qPCR) was carried out on CFX96 Real-Time PCR System (Bio-Rad) with SYBR 
Green Master Mix (Bio-Rad) with intron-spanning exonic primers listed in Table 2-5. 
Duplicate wells of each biological replicate with three or more biological replicates per 
genotype were used to calculate relative threshold cycle (Ct) values, which were 
normalized to reference genes cyclophilin A or cyclophilin B, which is indicated for each 
figure. To account for any differences in primer efficiency, all RT-qPCR results are 
shown as relative expression fold change, with the average of control samples set to 1. 
For the RNA-Seq, islets of all sizes from one mouse were used as one biological sample. 
Islet RNA samples from the STZ-treated animals were amplified for the RNA-Seq 
application using the Ovation RNA-Seq System V2 (Nugen). Illumina library 
preparation, sequencing on Illumina 2000/2500 instrument, and standard bioinformatics 
were performed at the JP Sulzberger Columbia Genome Center (New York, NY). 
Differential expression was determined by statistical testing based on negative binomial 
distribution using ‘DESeq’ package of the R software. Heatmaps were generated by 
normalizing FPKM values to the row mean and standard deviation values using the R 
software. Transcript reads were visualized with Integrative Genome Viewer (Broad 





Immunoprecipitation, immunoblotting, and mass spectrometry. Protein extracts were 
prepared using the whole cell lysis protocol of the Active Motif co-IP Kit (Active Motif). 
For co-immunoprecipitation, ~100 µg (~1/2 lysate of ~1000 pooled islets) or ~500 µg 
(Min6 lysates) of protein were incubated with rabbit anti-PKM2 (Cell Signaling), rabbit 
anti-IgG (Millipore), mouse anti-FLAG M2 magnetic beads (Sigma), or mouse anti-IgG 
(Millipore) overnight at 4 °C with rotation. Antibody-conjugated proteins were pulled 
down using protein G DynaBeads (Invitrogen) unless using the antibody-conjugated 
beads (FLAG). Immunoprecipitated proteins were washed, eluted, and analyzed by 
immunoblotting. Immunoblotting was performed by running denatured protein samples 
on a NuPAGE 10% or 4-12% Bis-Tris gel (Invitrogen), transferring onto a nitrocellulose 
membrane (GE Healthcare) and probing with mouse anti-FLAG (1:1000, Sigma), mouse 
anti-TUBULIN (1:2000, Santa Cruz), mouse anti-TBP (1:1000, Abcam), rabbit anti-
PKM2 (1:1000, Cell Signaling), mouse anti-PTPN2 (1:500, R&D Systems), rabbit anti-
PTPN2 (1:1000, Santa Cruz), or mouse anti-PCAF (1:500, Santa Cruz). Immunoblots 
were developed by the standard ECL method (Millipore) after probing with HRP-
conjugated secondary antibodies (1:10000, Jackson Immunoresearch). Western blot 
signals were quantified using the inverse density of light intensity measurements from the 
ImageJ software. FLAG-tagged Ptpn2 transfected cell lysates were co-
immunoprecipitated and sent for mass spectrometry at Herbert Irving Cancer Center 
Proteomics Facility (New York, NY). Proteomics Facility predicted proteins with the 
following discovery criteria: minimum two peptides per predicted protein and <1% false 
discovery rate. Results were visualized with Scaffold (Proteome Software). Two 
independent rounds of mass spectrometry data were consolidated prior to validation. 
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Immunohistochemistry and microscopy. Pancreata were dissected out, fixed in 10% 
formalin for 24 h at 4 °C, washed, transferred to ethanol, embedded in paraffin, and 
sectioned 5 µm-thick. After deparaffinization, antigen retrieval was performed with 10 
mM sodium citrate buffer (pH 6.0) or 10 mM Citrate-EDTA buffer (pH 6.2) for 20 min at 
95 °C prior to immunofluorescence. Sections were incubated overnight at 4 °C with 
guinea pig anti-INSULIN (1:1000, Dako), rabbit anti-GLUCAGON (1:100, Dako), goat 
anti-CPA1 (1:1000, R&D Systems), and rabbit anti-PKM2 (1:50, Cell Signaling), 
followed by 488-, Cy3-, and Cy5-conjugated secondary antibodies (1:500, Jackson 
Immunoresearch) and DAPI (1:1000, Invitrogen). Slides were imaged with Confocal 
Laser Scanning Microscope 710 and processed with the Zen Software (Zeiss). For 
histology, paraffin sections were deparaffinized and stained by the standard H&E 
protocol. Multiple slides from at least 3 different animals per genotype were imaged. 
 
Statistical analysis. Graphs were generated with the GraphPad Prism software. Results 
are expressed as mean ± SEM and significance testing was performed using a two-tailed 
Student’s t-test. Survival analysis was done using the Kaplan-Meier method and 






Figure 2-1. Ptpn2 βKO islets express Ptpn2 mRNA lacking the excised exons.  
(A) Schematic of the Ptpn2 transcripts with the number of exons indicated above. Exons 
5 and 6 are flanked by the loxP sites, indicated by the coral box. Below the schematic are 
primer sets P1, P2, and P3 aligned to the target sequences. (B) qPCR analysis of Ptpn2 
expression in control (Ctrl) or Ptpn2 βKO (KO) islets with floxed exon-specific (P2) or 
nonspecific (P1 and P3) primer sets, normalized to cyclophilin B reference gene (Ctrl N = 
6, KO N = 4). P < 0.01 (**). (C) RNA-Seq analysis of Ptpn2 aligned fragments in Ctrl 
(grey) and KO (coral histograms) islets, visualized by the IGV software, track range 10-






Figure 2-2. PTPN2 protein is deleted in Ptpn2 βKO islets.  
Expression analysis by Western blot of whole cell extracts from control (Ctrl) and Ptpn2 
βKO (KO) (A) islets and (B) hypothalamus, of PTPN2 (45 kDa) and loading controls 
TBP (37 kDa) or TUBULIN (55 kDa). (C) Quantification of PTPN2 signal intensity 
normalized to that of loading controls (N = 3 for each, although not shown in A and B). P 








Figure 2-3. Ptpn2 βKO mice are euglycemic. 
(A) Kaplan-Meier survival curve of control (Ctrl) and Ptpn2 βKO (KO) mice (Ctrl N = 
176, KO N = 96). (B-E) Metabolic measurements in 10-week-old mice. Ad lib and 
fasting blood glucose (B) (Ctrl N = 16, KO N = 14), and insulin (C) (N = 3 each). (D) 
Glucose tolerance test (GTT) and (E) insulin tolerance test (ITT) (Ctrl N = 8, KO N = 










Figure 2-4. Islet morphology is not altered in Ptpn2 βKO versus control islets. 
H&E-stained paraffin sections showing representative of islet morphology in Ptpn2 βKO 
(KO) and control (Ctrl) mice. Multiple sections from at least 3 animals of each genotype 







Figure 2-5. RNA-Seq analysis of Ptpn2 βKO and control islets. 
(A) RNA-Seq identified 1212 transcripts that are differentially expressed in control (Ctrl) 
and Ptpn2 βKO (KO) islets isolated from 8-week-old mice (N = 3 each). DESEQ P < 
0.05. (B) Table of key islet hormone transcripts, transcription factors expressed highly 
but not necessarily exclusively in beta cells, and genes associated with secretory granules 
or insulin secretory function. Statistically significant genes are in bold (DESEQ P < 
0.05). Log ratio is the log fold change of Ctrl to KO baseMean values from DESEQ 
analysis, where negative sign indicates downregulation in the KO samples. P, DESEQ P 
values. (C) Top 5 canonical pathways from IPA analysis of differentially expressed 
transcripts. Score, pathway enrichment score calculated from -log(Fisher P), with 








Figure 2-6. STAT3 is hyperphosphorylated in the Ptpn2 βKO islets. 
Western blot analysis of phosphorylated STAT3 at tyrosine 705 (86 kDa) in Ptpn2 βKO 









Figure 2-7. Ptpn2 βKO mice develop glucose intolerance upon high fat feeding 
comparable to that of the control mice. 
Three cohorts of animals were given high fat diet (HFD) at 10 weeks of age, and they 
were monitored for weight gain, ad lib and fasting blood glucose, as well as glucose and 
insulin tolerance. In the initial cohort, in which Ptpn2 βKO animals gained ~8 g less 
weight than the control, they exhibited improved glucose tolerance, but in the latter two 
cohorts, where weight gain was comparable, metabolic differences were not detected. 
Representative (A) GTT and (B) ITT from one of the two latter cohorts of animals with 






Figure 2-8. Ptpn2 βKO mice develop heightened diabetes with low-dose STZ. 
(A) Ad libitum blood glucose levels during (day -5 to day 0) and after five consecutive 
STZ administrations in multiple low-dose (MLD) STZ-induced diabetes in control (Ctrl) 
and Ptpn2 βKO (KO) mice (N = 5 each). (B) Area under the curve (AUC) of (A). (C) 
Glucose tolerance test (GTT) of MLD STZ mice three weeks after the final STZ 








Figure 2-9. Ptpn2 βKO islets display increased beta cell loss in STZ-diabetes. 
Islets from control (Ctrl) and Ptpn2 βKO (KO) animals 4 months after multiple low-dose 
injections of STZ were stained with anti-INSULIN (green), anti-GLUCAGON (red), and 
exocrine marker anti-CPA1 (blue). Multiple sections from at least 3 animals from 






Figure 2-10. Ptpn2 βKO mice show survival impairment with high-dose STZ. 
 (A) Ad libitum blood glucose levels of surviving control (Ctrl) and Ptpn2 βKO (KO) 
animals after single high-dose STZ induced diabetes (Ctrl N = 16, KO N = 17). The limit 
of our glucometer (600 mg/dl) is indicated by the dotted line. In order to plot the 
measurements beyond our limit, unreadable high measurements were assigned the same 
nonspecific value above the limit (800 mg/dl). (B) Kaplan-Meier survival curve of high-













Figure 2-11. Transcriptome analysis of STZ-Ptpn2 βKO islets. 
(A) RNA-Seq identified 819 transcripts that are differentially expressed in control (Ctrl) 
and Ptpn2 βKO (KO) islets isolated 5 days after a single high-dose STZ administration, 
shown as a heatmap (N = 2 each). DESEQ P < 0.05. (B) Table of key islet hormone 
transcripts, transcription factors expressed highly but not necessarily exclusively in beta 
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cells, and genes associated with secretory granules or insulin secretory function. 
Statistically significant genes are in bold (DESEQ P < 0.05). Log ratio and P, as in Figure 
2-5. (C) Top 5 canonical pathways from IPA analysis of differentially expressed 
transcripts. Score, as in Figure 2-5. (D) Validation qPCR analysis of genes in the top 
category, mitochondrial dysfunction, normalized to cyclophilin A reference gene (Ctrl N 









Figure 2-12. Integration of unstressed and post-STZ gene expression profiles. 
(A) Integration of the 1212 differentially expressed genes from unstressed (basal) islets 
and 819 differentially expressed genes in islets after STZ yielded 71 common genes, 
shown as a heatmap. DESEQ P < 0.05. (B) Top 3 network, toxic response, and canonical 









Figure 2-13. PTPN2 interacting proteins are involved in glucose metabolism. 
Tandem mass spectrometry (MS) analysis of eluates from FLAG immunoprecipitation of 
Min6 cells transfected with FLAG-tagged human PTPN2. (A) Top 5 canonical pathways 
from IPA analysis of MS-identified PTPN2-interacting proteins (N = 2). Score, as in 
Figure 2-5. (B) Schematic of the glucose metabolic flux. PTPN2 interacting proteins 
identified in both rounds of MS are indicated in bold, and those identified in only one 
round of MS are in italics. Coral box highlights pyruvate kinase M. PEP, 
phosphoenolpyruvate. TCA Cycle, tricarboxylic acid or Krebs cycle. Names of MS 







Figure 2-14. PTPN2 interacts with PKM1 and PKM2. 
Peptides mapping to PKM1 (A) or PKM2 (B) proteins are highlighted in yellow. 
Representative coverage of one of the hPTPN2-WT-Flag-transfected sample is shown. 
Most peptides map to both isoforms. Region of 55 amino acids of either exon are 
indicated by the coral outline. Amino acids in green are tags used in the MS protocol. (C) 
Spectral counts of peptides mapping exclusively to PKM1 or PKM2 in both rounds of 
mass spectrometry (MS1 and MS2). (D) RNA-Seq analysis of Pkm-aligned fragments in 
control (grey) and Ptpn2 βKO (coral) islets (IGV track range 200-300). Alternatively 
spliced exons indicated by the black box (exon 9 excised out in Pkm2, exon 10 excised 







Figure 2-15. PTPN2 interacts with PKM2 in vitro and in vivo. 
!(A) Validation immunoprecipitation (IP) and Western blot using identical IP conditions 
as mass spectrometry sample preparation. Western blot representative of three separate 
transfections for each plasmid. (B) Reciprocal IP with PKM2 antibody using whole cell 
extracts from pooled mouse islets. IgG, non-specific antibody control for IP. Dashed line 












Figure 2-16. PKM2 translocates to the nuclei in diabetic islets.  
Subcellular localization of PKM2 in healthy and STZ-diabetic islets. Diabetic condition 
is within one week after a single high-dose injection of STZ. Control islets from healthy 
(A) and STZ (B) mice, and Ptpn2 βKO islets from healthy (C) and STZ (D) mice were 
stained with anti-INSULIN (red), anti-PKM2 (green), and nuclear stain DAPI (white). 
Multiple sections from at least 3 animals of each condition were stained. Merged images 
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are shown. Framed regions are zoomed and separated by channel on the right side. Scale 
bar, 30 µm. (E) Line profiles of relative fluorescence intensities of INSULIN (red), 
PKM2 (green), and DAPI (white) signals from the framed cells of corresponding panels 








Figure 2-17. PKM2 nuclear translocation is modulated by PTPN2. 
Min6 cells were transfected with constructs encoding wildtype (WT-Flag) and functional 
mutant (DA-Flag) human PTPN2. After exposing the cells to 1 mM STZ for 24 hours, 
nuclear fractions were extracted. Cells transfected with mutant PTPN2 displayed 
decreased PTPN2 and increased nuclear PKM2. Cells not subjected to STZ stress did not 









Figure 2-18. A subset of upregulated transcripts are HIF-1α targets.  
(A) 70 validated and predicted HIF-1α-induced genes were compiled from literature. 
Regardless of the statistical significance from DESEQ analysis, visual inspection via 
heatmap representation of the FPKM values shows an overall upregulation of HIF-1α-
induced genes in the Ptpn2 βKO (KO) versus control (Ctrl) islets from STZ-diabetic 
mice. (B) Statistically significant HIF-1α target transcripts are shown. DESEQ P < 0.05. 
(C) Validation qPCR analysis of HIF-1α target genes, as well as expression of Hif1a and 
Pkm2, normalized to cyclophilin A reference gene (Ctrl N = 5, KO N = 4). P < 0.05 (*), P 




Figure 2-19. Ex vivo reconstitution of proposed PTPN2 function in Ptpn2 βKO islets 
rescues the transcriptional alterations. 
(A) Schematic of the reconstitution experiment. Islets were isolated from Ptpn2 βKO 
mice, and islets in culture were stressed with STZ with or without the PKM2 tetramer 
activator, TEPP46, after a period of pretreatment conditions. Equal amounts of DMSO 
were used as a vehicle control for TEPP46, and sodium citrate buffer was used as a 
vehicle control for STZ. Function of TEPP46 is indicated below. (B) Gene expression 
changes in isolated Ptpn2 βKO islets treated with STZ and TEPP46 compared to no 
treatment islets or islets treated with STZ alone, normalized to cyclophilin A reference 
gene (N = 3 each). Ptpn2 transcripts were assayed with primer sets in Figure 2-1 and the 
majority of the transcripts were floxed transcripts in all samples compared to islets from 
control mice. Y-axis labels (relative expression) left out for visual simplicity. Color 











Figure 2-20. Proposed model depicts PTPN2 as the regulator of nuclear PKM2 in 
pro-apoptotic beta cells. 
(A) In healthy beta cells with normal mitochondrial function, PKM2 is cytosolic. (B) In 
pro-apoptotic beta cells, as in STZ stress, PKM2 translocates to the nucleus and mediates 
HIF-1α-responsive transcription. PTPN2 balances the levels of nuclear PKM2, as does 
tetramer activator TEPP46. It is also possible that PTPN2 binds to the cytosolic PKM2, 
stabilizing its tetramer conformation. (C) In the absence of PTPN2, nuclear PKM2 
accumulates, and activates HIF-1α/PKM2-mediated transcription with vigor, leading to 





Table 2-1. RNA-Seq analysis of differentially expressed genes in diabetic islets  
 

























cytochrome P450, family 2, subfamily 













cell death-inducing DNA fragmentation 
factor, alpha subunit-like effector A 
Cide-A 
 
Egln3 0.6 36.7 65.14 0.0299 egl-9 family hypoxia-inducible factor 3 Hif-p4h-3 
Hamp 7.1 401.9 56.31 0.0455 hepcidin antimicrobial peptide Hepc1 
Ppbp 2.6 62.5 24.35 < 0.0001 pro-platelet basic protein Cxcl7 
Il22ra2 1.3 25.4 19.04 0.0070 interleukin 22 receptor, alpha 2 Il-22bp 












inorganic pyrophosphate phosphatase 
Hdhd2b 
 































Cxcl13 0 52.0 - < 0.0001 chemokine (C-X-C motif) ligand 13 Angie2 
Hoxd9 0 19.3 - 0.0041 homeobox D9 Hox-5.2 
Slc17a1 0 17.9 - 0.0055 solute carrier family 17, member 1  Npt1 
Hoxc6 0 15.8 - 0.0115 homeobox C6 Hox-3.3 
Coro6 0 15.1 - 0.0153 coronin 6 - 
Aox3 0 16.3 - 0.0229 aldehyde oxidase 3 Aoh2 
H2-M9 0 30.2 - 0.0248 histocompatibility 2, M region locus 9 M9 
Hgd 0 16.8 - 0.0252 homogentisate 1,2-dioxygenase Aku 
Il31ra 0 11.6 - 0.0381 interleukin 31 receptor A Gpl 
Tectb 0 11.3 - 0.0420 tectorin beta  Tctnb 
 





























Gm872 14.7 0.5 0.036 0.0282 chromosome 12 open reading frame 55 C12orf55 
Tas1r1 13.0 0.5 0.040 0.0350 taste receptor, type 1, member 1 Tas1r1 















Rs1 12.2 0.5 0.043 0.0480 retinoschisin 1 Xlrs1 

































Table 2-1. RNA-Seq analysis of differentially expressed genes in diabetic islets.  
DESEQ analysis of differentially expressed transcripts from control (Ctrl) and Ptpn2 
βKO (KO) islets isolated 5 days after STZ treatment. After filtering for statistical 
significance (DESEQ P < 0.05), transcripts were sorted by the magnitude of fold change 
(KO/Ctrl baseMean values). Listed are the top 10 upregulated genes (A) and top 10 
downregulated genes (C) in the order of fold change magnitude. In (B), transcripts only 
detected in KO islets are listed. No differentially expressed transcripts were only detected 
in Ctrl islets. Ctrl and KO columns list baseMean values from the DESEQ analysis (N = 







Table 2-2. Mass spectrometry-identified PTPN2-interacting proteins 
 
Gene WT DA EV D:W Spec% Description Accession 
Hspa5  281 240 105 85 60 78 kDa glucose-regulated protein P20029 
Tubb5  209 188 79 90 60 cluster of Tubulin beta-5 chain P99024 
Acly 192 157 67 82 62 ATP-citrate synthase  Q3V117 
Pkm 134 108 46 81 62 cluster of Pyruvate kinase M P52480 
Vcp 118 103 40 87 64 transitional ER ATPase  Q01853 














calcium ATPase 2 
O55143 
 
P4hb 81 56 25 69 64 protein disulfide-isomerase  P09103 
Hnrnpk 78 57 26 73 61 heterogeneous nuclear ribonucleoprotein K P61979-2 
Atp5b 61 55 26 90 55 ATP synthase subunit beta, mitochondrial  P56480 
Ppm1b 49 51 19 104 62 protein phosphatase 1B, Mg dependent Q99NF7 
Uba1 42 25 6 60 82 ubiquitin-like activating enzyme 1 Q02053 
Cct3 30 20 0 67 100 T-complex protein 1 subunit gamma P80318 
Gapdh 40 35 14 88 63 glyceraldehyde-3-phosphate dehydrogenase P16858 
Dpysl2 34 23 7 68 75 dihydropyrimidinase-related protein 2 O08553 
Ganab 29 20 3 69 88 isoform 2 of Neutral alpha-glucosidase AB  Q8BHN3 
Pdia6 27 24 5 89 80 protein disulfide-isomerase A6  Q3TML0 
Eif4b 39 39 19 100 51 eukaryotic translation initiation factor 4B  Q8BGD9 
Ddx3x 29 20 5 69 80 cluster of ATP-dependent RNA helicase Q62167 
Actn4 28 11 0 39 100 cluster of Alpha-actinin-4 P57780 
Alb 39 25 13 64 59 serum albumin P07724 
Cltc 24 12 0 50 100 clathrin heavy chain  Q5SXR6 













cluster of Sodium/potassium-transporting 
ATPase subunit alpha-1 
Q8VDN2 
 
Aco2 20 13 0 65 100 aconitate hydratase, mitochondrial  Q99KI0 
Ero1lb 17 21 3 124 84 ERO1-like protein beta  Q8R2E9 
Hyou1 23 8 0 35 100 hypoxia up-regulated protein 1  Q9JKR6 
Ddx5 29 19 9 66 63 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 5 
Q61656 
Cct4 18 12 0 67 100 T-complex protein 1 subunit delta  P80315 
Mcm2 21 12 2 57 88 DNA replication licensing factor P97310 
Hnrnpu 21 7 0 33 100 heterogeneous nuclear ribonucleoprotein U  Q8VEK3 
Fasn 16 9 0 56 100 fatty acid synthase  P19096 
Mcm3 18 7 0 39 100 DNA replication licensing factor P25206 
Mdh2 21 15 6 71 67 malate dehydrogenase, mitochondrial  P08249 
Mthfd1 18 5 0 28 100 C-1-tetrahydrofolate synthase, cytoplasmic  Q922D8 
Hadha 22 14 7 64 61 trifunctional enzyme subunit alpha Q8BMS1 
Mcm5 14 8 0 57 100 DNA replication licensing factor P49718 
Cct2 12 13 2 108 84 T-complex protein 1 subunit beta  P80314 
Nsf 12 8 0 67 100 N-ethylmaleimide sensitive fusion protein P46460 
Ap1b1 14 6 0 43 100 cluster of AP-1 complex subunit beta-1   O35643 
Ap3b2 9 10 0 111 100 cluster of AP-3 complex subunit beta-2   Q9JME5 
Khsrp 10 6 0 60 100 far upstream element-binding protein 2  Q3U0V1 
Idh2 13 9 4 69 64 isocitrate dehydrogenase, mitochondrial  P54071 
Oat 5 9 0 180 100 ornithine aminotransferase, mitochondrial  P29758 













thyroid hormone receptor-associated 
protein 3  
Q569Z6 
 
Pgk1 8 9 4 113 53 cluster of Phosphoglycerate kinase 1   P09411 
Srrm2 5 0 0 0 100 serine/arginine repetitive matrix protein 2 Q8BTI8 
!
 99 
Table 2-2. Mass spectrometry-identified PTPN2-interacting proteins. 
Tandem mass spectrometry (MS) analysis of eluates from FLAG-immunoprecipitation of 
Min6 cells transfected with Flag-tagged wildtype (WT) or substrate-trapping mutant 
(DA) forms of human PTPN2, or empty vector control (EV). Two rounds of MS were 
consolidated for proteins identified in both rounds. Numbers in WT, DA, and EV 
columns are spectral intensities from the second round of MS, which had much higher 
peptide coverage. D:W is the ratio of DA to WT spectral intensities, represented as a 
percentage. Spec% is the specificity, calculated by subtracting the background EV 
intensity from the average of WT and DA, represented as a percentage of the average of 
WT and DA. The list shows proteins of very specific interactions with PTPN2 (filtered 
by Spec% > 50%) in the order of specificity weighted by spectral intensity. Accession 






Table 2-3. IPA-identified transcripts downstream of HIF-1α 
  





solute carrier family 2 (facilitated 





















v-maf avian musculoaponeurotic 





Lox 2.458 lysyl oxidase Upregulates (9) Activated 
Igf1 2.165 insulin-like growth factor 1 Upregulates (2) Activated 
Hist1h1c 2.149 histone cluster 1, H1c Upregulates (1) Activated 
Gbe1 1.457 glucan (1,4-alpha-), branching enzyme 1 Upregulates (1) Activated 
Fhl3 3.839 four and a half LIM domains 3 Upregulates (1) Activated 





BCL-2/adenovirus E1B 19kDa 









BCL-2/adenovirus E1B 19 kDa 





Apoe 1.833 apolipoprotein E Upregulates (2) Activated 
Aldoa 1.468 aldolase A, fructose-bisphosphate Upregulates (6) Activated 
Kifc2 -1.654 kinesin family member C2 Upregulates (1) Inhibited 











Hamp 5.815 hepcidin antimicrobial peptide Regulates (2) Affected 
 
Table lists 19 differentially expressed transcripts from RNA-Seq that were categorized as 
being downstream of HIF-1α by the IPA software’s Upstream Analysis function. Log 
ratio is the log fold change of control (Ctrl) to Ptpn2 βKO (KO) baseMean values, where 
negative sign indicates downregulation in KO samples. HIF-1α effect column lists known 
HIF-1α effect the transcript expression, with number of published articles to this effect in 
parenthesis. HIF-1α state column lists prediction of HIF-1α activation or inhibition 
upstream of these transcripts, based on the consolidation of log ratio direction with 
























       
Pro-survival 
Bcl2 233.7 262.1 0.165 0.8427 B cell leukemia/lymphoma 2  
Bcl2l2 352.9 289.4 -0.286 0.6801 BCL-2-like 2 BCL-W 
Bcl2a1a 9.3 0.9 -3.356 0.4803 BCL-2-related protein A1a A1 
Bcl2l10 3.3 1.6 -1.082 0.7798 BCL-2-like 10 Boo 
       
Pro-apoptotic 
Bax 183.5 154.8 -0.246 0.8070 BCL-2-associated X protein  
Bok 2.4 16.2 2.778 0.1055 BCL-2-related ovarian killer  
Bak1 75.8 69.4 -0.127 0.8966 BCL-2-antagonist/killer 1 BAK 
Bcl2l14 0.0 0.9 - 0.8899 BCL-2-like 14 BCL-GL 
Bcl2l15 7.0 1.7 -2.013 0.4853 BCL-2-like 15 BFK 
Pro-apoptotic, BH3-only 
Bad 34.8 48.0 0.464 0.4859 BCL-2-associated agonist of death  
Bik 11.0 8.0 -0.458 0.7431 BCL-2-interacting killer  
Bid 18.0 31.4 0.809 0.4239 BH3 interacting domain death agonist  
Hrk 2.8 5.1 0.844 0.8264 activator of apoptosis harakiri DP5 












induced protein 1 
NOXA 
 
Bbc3 44.5 19.4 -1.196 0.2427 BCL-2-binding component 3 PUMA 











BCL-2/adenovirus E1B 19kDa 











BCL-2/adenovirus E1B 19kDa 
interacting protein 3  
       
Both pro-survival and pro-apoptotic 
Bcl2l1 354.3 337.1 -0.072 0.8607 BCL-2-like 1 BCL-X 
Mcl1 900.0 1694.1 0.913 0.0621 myeloid cell leukemia 1  
 
Table lists transcripts encoding BCL-2 family proteins listed in Figure 1-4 and additional 
known BCL-2 family members, with expression baseMean values from control (Ctrl) and 
Ptpn2 βKO (KO) islets 5 days after STZ treatment. P, DESEQ P values. Log ratio is the 
log fold change of baseMean values. Statistical significance indicated by *. Bcl2l1 and 
Mcl1 both encode long and short forms that function in pro-survival and pro-apoptotic 
pathways, respectively. Pro-apoptotic Bok and Bcl2l11, as well as dual-functioning Mcl1 




Table 2-5. Primer sequences 
 
Gene Forward Reverse cDNA gDNA 
Ptpn2_P1 GATGTGCAAAGCAAGACCTGAAG TGCAAGTCTTCTGCTGGTGG 141 141 
Ptpn2_P2 AACACATGCTGCCATTTCTG CACACTGAATCCCGTTTCCT 156 7469 
Ptpn2_P3 ATCGAGCGGGAGTTCGA TCTGGAAACTTGGCCACTC 110 12624 
CycA CAGTGCTCAGAGCTCGAAAGT GTGTTCTTCGACATCACGGC 109 2324 
CycB GCAAAGTTCTAGAGGGCATGGA CCCGGCTGTCTGTCTTGGT 63 686 
Sod2 GCTTGATAGCCTCCAGCAAC ACTGAAGTTCAATGGTGGGG 107 2903 
Sod1 TACTGATGGACGTGGAACCC GAACCATCCACTTCGAGCA 103 1953 
Atp5b GGGTCAGTCAGGTCATCAGC CACAATGCAGGAAAGGATCA 90 1990 
Ndufa4 TCTGGGCCTTCTTTCTTCAG CCAGAGCCATGGAACAAACT 92 4703 
Cat CCCGCGGTCATGATATTAAGT GATGAAGCAGTGGAAGGAGC 102 8154 
Cyb5a AGGACTTCTTCTCCACCAGGA GCACAAAGACAGCAAGAGCA 96 19993 
Sdha AACAGAGAAGTGAAAGCCGC CGCAGTTTCGAGGCTTCTT 97 5305 
Bnip3 TGAAGTGCAGTTCTACCCAGG CCTGTCGCAGTTGGGTTC 94 10628 
Egln3 CTGGATAGCAAGCCACCATT CATCAACTTCCTCCTGTCCC 110 17654 
Bnip3l CCATTTCCATTCTCATTGCC AACAACAACTGCGAGGAAGG 110 9093 
Ldha GTGCCCAGTTCTGGGTTAAG CTGGGTCCTGGGAGAACAT 99 917 
Slc2a1 GAGTGTGGTGGATGGGATG AACACTGGTGTCATCAACGC 99 11735 
Ddit4 ACAGGTGCTCATCCTCGG CTGGACAGCAGCAACAGTG 109 396 
Pkm2 CTCTGGAGGCTGTTCGCATG  GGCGGAGTTCCTCGAATAGC  87 3581 
 
 
Sequences of qRT-PCR primers designed using Primer-BLAST (NCBI). cDNA, base 
pair amplicon size of the transcript. gDNA, genomic DNA amplicon size, maximized 
















Chapter Three: Identification of novel type 1 diabetes candidate genes by 
integrating non-obese diabetic mouse islet gene expression and CpG methylation 
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Genome-wide association studies (GWAS) in humans have linked over 40 loci to type 1 
diabetes (T1D) susceptibility. Although many of the genes nested in these loci have not 
been functionally linked to disease pathogenesis, many are expressed in the human islets, 
suggesting that the beta cells of certain individuals may be predisposed to autoimmunity. 
To identify candidate genes that could influence beta cell susceptibility to insulitis, we 
integrated the human T1D GWAS data with differential RNA transcriptome and DNA 
methylome of insulitis-susceptible (NOD) versus resistant (NOR) murine pancreatic 
islets, prior to the autoimmune assault. Aligning the 312 positional candidate genes from 
52 GWAS-orthologous regions to the 1745 genes that were differentially expressed in 
NOD versus NOR islets identified 30 known and novel diabetes candidate genes. Further 
incorporation of the DNA methylation data identified three potential islet-specific T1D 
candidates that may be involved in disease pathogenesis. Together, our study describes a 
useful approach in identifying T1D susceptibility genes through integrating mouse gene 





The pathogenesis of type 1 diabetes (T1D) involves the interplay of injurious 
immune cells and the targeted pancreatic beta cells that result in autoimmune insulitis and 
gradual beta cell destruction over the course of months to years (Todd, 2010). Human 
genome-wide association studies (GWAS) have linked over 40 loci to T1D susceptibility 
(Barrett et al., 2009). However, many of these loci span large genomic regions containing 
multiple transcripts, hindering efforts to identify a specific causal gene in a given 
susceptibility locus. Identification of functional candidate genes through transcriptome 
analysis is further complicated by the multidimensional nature of T1D etiology. Twin 
studies have shown that T1D is highly concordant over a long-term follow up (Redondo 
et al., 2008), but even with identical genetics, monozygotic twins do not necessarily have 
the same risk for T1D at a single time point (Barnett et al., 1981), suggesting 
environmentally-induced non-genetic factors may also be involved. Consistent with this 
idea, epigenetic modifications such as DNA methylation and histone modifications have 
been associated with altered gene expression in T1D (Dang et al., 2013). 
The non-obese diabetic (NOD) mouse strain develops spontaneous autoimmune 
diabetes similar to human T1D (Atkinson and Leiter, 1999; Makino et al., 1980). In NOD 
mice, immune cells are targeted to the pancreatic islets around 4-8 weeks, where they 
infiltrate and destroy the beta cells beginning around 12 weeks, and eventually cause 
overt diabetes by 16-24 weeks (Anderson and Bluestone, 2005). Gene expression 
profiling of NOD islets during the various stages of insulitis has been instrumental in 
identifying a conserved sequence of immunological activation and inflammatory 
responses during the progression to T1D (Carrero et al., 2013). Such an unbiased 
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approach to identify pivotal changes throughout T1D offers insights into the events 
leading up to disease initiation; however, a major challenge associated with these global 
expression datasets is prioritizing functional candidate genes and identifying those that 
are associated with human T1D initiation and progression. Similarly, development of 
diabetes in the NOD mice is not fully penetrant, suggesting DNA methylation may also 
play a role in predisposing NOD islets to insulitis.  
The present study was designed to identify novel candidate genes that may 
contribute to T1D by integrating the gene expression and DNA methylation profiles of 
non-obese insulitis-resistant NOR and insulitis-sensitive NOD mouse islets with the 
human T1D GWAS susceptibility loci. Alignment to the mouse positional candidate 
genes identified in the human GWAS identified 30 differentially expressed candidate 
genes, some of which have been studied in the context of diabetes while others are novel 
candidates. We did not find any differentially methylated genes that were identified in the 
human GWAS, but three hypomethylated genes had correlated increases in gene 




Gene expression changes in NOD islets are enriched for human diabetes candidate 
genes.  
To identify transcriptional changes associated with insulitis-prone islets, we 
isolated islets from NOD and NOR mice at 4 weeks of age, and identified their respective 
RNA profiles by high throughput sequencing. The four-week time point was chosen to 
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optimize the degree of islet maturity, while avoiding any secondary changes induced by 
insulitis (Carrero et al., 2013). To control for beta cell-specific changes, we used the 
genetically similar NOR strain that has the NOD congenic adaptive immune system, but 
does not initiate an autoimmune response (Prochazka et al., 1992). Transcriptome 
analyses identified 1745 transcripts that were differentially expressed (DESEQ P < 0.05) 
in the insulitis-prone islets. Biological pathway analysis of these genes revealed 
enrichment in immune response signatures (Fig. 3-1), in agreement with a previous NOD 
islet study that identified immune response signatures as early as 4 weeks, despite the 
islets having less than 0.1% CD4 and CD8 immune cells by flow cytometry (Carrero et 
al., 2013).  
 To discover novel gene expression changes that were potentially relevant for 
human T1D, we evaluated the overlap of the 1745 differentially expressed transcripts 
with the genes residing in regions of the mouse genome that were orthologous to the 
human T1D susceptibility loci. Because many of these positional candidate genes 
identified in the human loci have not been previously studied in the context of diabetes, 
the comparative data represents a source of potential T1D candidate genes. The overlap 
revealed that 30 protein-coding positional candidate genes from the human loci are 
differentially expressed in the NOD islets (Fig. 3-2). This list contained some well-known 
T1D candidate genes such as cathepsin H (Ctsh), but also revealed many candidate genes 
not previously implicated in T1D etiology, including osteosarcoma amplified 9 (Os9). 
Expanding the analysis to encompass non-protein-coding transcripts identified additional 
genes, including the known candidate gene maternally expressed 3 (Meg3), which has 
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been linked to both type 1 (Wallace et al., 2010) and type 2 diabetes (Kameswaran et al., 
2014) (data not shown).  
 
Islet CpG methylation changes in insulitis-prone islets.  
To investigate whether there was a correlation of CpG methylation and gene 
expression changes in the NOD islets, we prepared CpG site-enriched reduced 
representation bisulfite sequencing (RRBS) DNA libraries (Gu et al., 2011) from 4-week-
old NOD and NOR islets to perform methylation sequencing. Differentially methylated 
region (DMR) analysis with stringent discovery criteria compiled 46 unique genomic 
regions that were differentially methylated in the NOD islet genome. Of these regions, 41 
mapped within or in close proximity (< 60 kb from the transcriptional start site) to 
protein-coding genes; 38 were hypomethylated in NOD islets and 3 were 
hypermethylated. Eight of the CpG regions were not located within 60 kb of the 
transcriptional start site of any single gene. Of the 38 hypomethylated regions, three 
genes were identified by duplicate DMRs: erbin (Erbb2ip), forkhead box A2 (Foxa2), and 
UPF1 regulator of nonsense transcripts homolog (Upf1). All other genes were mapped 
by single DMR regions, with a total of 38 differentially methylated genes (Table 3-1). 
Interestingly, many of these genes have not been previously implicated in beta cell 
pathophysiology and T1D. We aligned the 38 differentially methylated genes with the 
T1D positional candidate genes and did not identify any overlap. However, three of the 
hypomethylated genes were identified in the RNA-Seq to be significantly upregulated in 
the NOD islets: eukaryotic translation initiation factor 4a1 (Eif4a1), collagen type 1 
alpha 1 (Col1a1), and FAT atypical cadherin 1 (Fat1). Collectively, integration of the 
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NOD versus NOR transcriptome results with human GWAS and islet DNA methylation 
data led to the identification of potential T1D candidate genes in NOD islets which may 
be beta cell modulators of diabetogenesis. 
 
Discussion 
Using the NOD mouse model of T1D, we identified gene expression and 
methylation changes in insulitis-prone and insulitis-resistant mouse islets. By combining 
the islet datasets with positional candidate genes derived from the human GWAS loci, we 
found 30 differentially expressed candidate genes. By combining the dataset further with 
CpG methylation data, we found three additional candidate genes that may be regulated 
by promoter methylation.  
Some of the candidate genes identified by RNA-Seq have been previously 
implicated in diabetes or beta cell function, which allowed us to use them as internal 
positive controls to validate our data mining approach. One such gene, Ctsh, has recently 
been reported to affect disease progression in newly diagnosed pediatric patients (Floyel 
et al., 2014). The authors propose increased Ctsh expression in beta cells as a potential 
mechanism of protection against immune damage. Our data shows that Ctsh expression is 
downregulated in NOD islets (Fig. 3-2), perhaps suggesting that even at this early pre-
insulitic time point, NOD islets have compromised protection against immune damage.  
Among the novel candidate genes, Os9 is upregulated in NOD islets. Os9 is 
upregulated in response to endoplasmic reticulum (ER) stress in mammalian cell lines 
(Alcock and Swanton, 2009), and it has been established that in 6-, 8-, and 10-week-old 
islets, beta cell ER stress precedes clinical diabetes in the NOD mouse model (Tersey et 
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al., 2012). At the studied time points, there is progressive insulitis, but the fact that Os9 is 
upregulated in our 4-week-old NOD islets suggests that ER stress may in fact be present 
much earlier than reported and possibly before significant insulitis. This suggests that 
there are beta cell intrinsic differences in insulitis-prone and insulitis-resistant islets.  
Another novel candidate was ribosomal protein S6 kinase, polypeptide 2 
(Rps6ka2), which encodes a ribosomal S6 kinase family member of serine/threonine 
kinases that act as downstream effectors of the mitogen-activated kinase (MAPK) 
signaling pathway to modulate cell survival and proliferation (Anjum and Blenis, 2008). 
This gene has been associated with diabetic cataracts in type 2 diabetics (Lin et al., 2013), 
as well as pancreatic (Milosevic et al., 2013), colorectal (Slattery et al., 2011), and 
ovarian (Bignone et al., 2007) cancer models. In fact, several of our novel candidates 
from the RNA-Seq/GWAS overlap had been identified in the context of cancer, including 
teratocarcinoma-derived growth factor 1 (Tdgf1), breast cancer anti-estrogen resistance 
1 (Bcar1), and Os9. Furthermore, DMR candidate genes also included a number of genes 
that are oncogenic, including erbin (Erbb2ip), also known as ERBB2 interacting protein. 
Much like the aberrant cancer cell environment, it is possible that these gene products 
produce a dysfunctional beta cell milieu leading to immune targeting and diabetes. How 
this leads to beta cell death as opposed to tumor-like proliferation is not well understood, 
and it may be worthwhile to study these genes in primary beta cells and tumor tissues. 
Of the three hypomethylated genes with correlating increases in gene expression, 
none had been previously implicated in T1D pathogenesis or beta cell function. Col1a1 
had been studied as a genotypic marker to identify T1D patients with lower bone mineral 
density and higher risk for osteopenia, a common complication of T1D (Hampson et al., 
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1998). Fat1 is an oncogenic gene that is highly upregulated in glioblastoma, and mediates 
inflammation and neoplasia (Dikshit et al., 2013). Because the expression of these genes 
appears to be influenced by promoter methylation at an early age, it would be interesting 
to study the functions of EIF4A1, COL1A1, and FAT1 in the context of beta cell 
development, function, and inflammation.  
Most of the genes identified by islet CpG methylation differences were not 
significantly changed in RNA expression. However, it is possible that the methylation 
signatures are maintained over time, and islet gene expression at the time of immune 
attack may be significantly different. It is worthwhile to mention that nitric oxide 
synthase interacting protein (Nosip) is hypomethylated in the NOD islets. In neuronal 
cell types, neuronal nitric oxide synthase (nNOS) interacted with NOSIP and the protein 
complex colocalized with synapses in rat brains (Dreyer et al., 2004). Overexpressing 
NOSIP decreased nNOS in tertiary dendrites, and authors suggest that NOSIP sequesters 
nNOS to prevent nNOS trafficking to distal dendrites. Beta cells also express nNOS, 
which localizes to the membrane of insulin secretory granules where it is critical for 
insulin secretion (Lajoix et al., 2001). It is unknown whether NOSIP is also expressed on 
the membrane of the insulin granules, but drawing a parallel from the neurons, NOSIP 
interaction may also be the mechanism in beta cells that spatially restricts nNOS to the 
insulin granules. Hypomethylation of the CpG region in the promoter of Nosip suggests 
less steric hindrance for Nosip gene expression. It is thus possible that NOD islets may 
overexpress Nosip at a later time point, which may decrease nNOS on insulin granules 
and play a role in beta cell dysfunction. Additionally, pro-inflammatory cytokines 
promote nitric oxide production by inducing the expression of inducible nitric oxide 
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synthase (iNOS) to trigger beta cell apoptosis (Kaneto et al., 1995) and ER stress 
(Oyadomari et al., 2001). It is not known whether NOSIP interacts with iNOS, but if it 
does, it could shed new light on regulatory mechanisms of beta cell apoptosis. 
Our study is somewhat limited by the variable diabetes phenotype in the NOD 
mice. Although we limited our study to the female mice, which have higher (80%) T1D 
penetrance than their male counterparts (30%), not knowing which mouse would have 
become diabetic in the future could have diluted our dataset if our sample mice were to 
be diabetes-free by chance. We tried to address this by increasing the number of 
replicates (N = 6 for the NOD), and by visualizing the sample-to-sample heterogeneity 
within genotypes with heatmaps and hierarchical clustering analysis, it was clear that 
most of the NOD samples were distinct from the NOR islets. For example, in Figure 3-2, 
the NOD sample in column 5 mirrors the NOR samples for many of the genes, and 
perhaps this replicate contained islets from mice that would have been more diabetes-
resistant. This could have diluted the significance statistic in differential expression and 
methylation analysis and perhaps this led to the exclusion of some critical candidate 
genes. Another caveat is that the NOD mouse model, although it is a well-validated 
model of T1D, has some type 2 diabetes (T2D) characteristics (Chaparro et al., 2006). 
This may in fact be an advantage in identifying diabetes candidate genes in our datasets, 
because in humans, clinical similarities have blurred the distinction between different 
classifications of diabetes (Cervin et al., 2008). We kept this in mind when categorizing 
candidate genes as novel. One of the hypomethylated genes, Foxa2, is not a reported T1D 
candidate but is a well confirmed T2D gene (Banasik et al., 2012; Tabassum et al., 2008) 
that controls the expression of important beta cell transcription factors such as 
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neurogenin 3 (Ngn3), forkhead box protein O1 (FoxO1), and pancreatic and duodenal 
homeobox 1 (Pdx1) (Chen et al., 2011; Ejarque et al., 2013; Lee et al., 2002). Our 
identification of T2D-associated Foxa2 hints at the usefulness of the NOD mouse model 
in studying T2D as well as T1D, and further analysis of beta cell Foxa2 promoter 
methylation in diabetic islets and diabetes-susceptible islets may help us to understand 
the epigenetic mechanisms of beta cell dysfunction.  
Other limitations of the study include the RRBS method of detecting differential 
methylation, which covers genomic regions with relatively high CpG density, 
overlooking regions that are not CpG-rich. Other methods with higher genomic coverage 
that may be used to detect DMRs include affiny-based methods such as methylated DNA 
immunoprecipitation deep sequencing (MeDIP-Seq) and methylated DNA capture by 
affinity purification (MethylCap-Seq). However, comparative analysis of the DMR 
detection methods concluded that despite lower genomic coverage, the RRBS method 
yields accurate DNA methylation levels, because CpG-rich sequences are most 
consistently methylated overall and CpG-poor sequences have variable methylation 
levels within biological replicates (Bock et al., 2010). Moreover, we annotated each 
DMR as regulating the gene that is most proximal to the DMR. Methylated DNA can 
impose steric hindrance to the chromatin, but we cannot rule out the possibility that 
differential methylation of a regulatory region that is far from the promoter of a gene may 
also regulate the chromatin structure through tertiary interactions. And lastly, interplay of 
DNA methylation, histone modifications, and non-coding RNAs may coordinately 
regulate differential gene expression in the NOD versus NOR islets, and limiting our 
study to just DMRs may overlook important epigenetic mechanisms.  
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In conclusion, even with some limitations, we have successfully identified novel 
candidate genes for T1D, including three genes with correlating RNA expression and 
DNA methylation changes. Integrating positional candidate genes from GWAS with 
disease-susceptible mouse data is a powerful method to analyze high throughput datasets. 
Such global integrative screening prior to molecular characterization and functional 
confirmation of the candidate genes has the potential for a more efficient and possibly 
more clinically relevant candidate gene selection that could lead to a better understanding 
of T1D. 
 
Materials and Methods 
 
Mice. Female NOD/ShiLtJ (NOD) and NOR/LtJ (NOR) mice were obtained from the 
Jackson Laboratories (Bar Harbor, ME) and their islets were harvested within a week of 
arrival at our facility to limit environmental effects. All animal studies were approved by 
the Institutional Animal Care and Use Committee at the Columbia University Medical 
Center.  
 
Islet isolation. Pancreatic islets were isolated from 4-week-old NOD and NOR mice, 
following a modified version of published protocol (Gotoh et al., 1985). After 
handpicking, islets were flash-frozen and stored at -80 °C until processing.   
 
RNA-Seq analysis. For each sample, islets from two mice were pooled to make one 
biological replicate. Total RNA was extracted using either the RNeasy Micro Kit or Mini 
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Kit (Qiagen). Illumina library preparation, sequencing on Illumina 2000/2500 instrument, 
and standard bioinformatics were performed at the Columbia Genome Center (New York, 
NY). Differential expression was determined by statistical testing based on negative 
binomial distribution using ‘DESeq’ package of R software.  
 
Methylation analysis. For each sample, islets from three mice were pooled to make one 
biological replicate. Genomic DNA was extracted from isolated islets and purified with 
two to three rounds of the standard phenol-chloroform extraction. Reduced representation 
bisulfite sequencing libraries were prepared as described (Gu et al., 2011), and libraries 
were sequenced with 36-bp single-end sequencing with 10 million aligned reads per 
library on the Illumina Genome Analyzer II. Raw reads were aligned using Genomic 
Short-read Nucleotide Alignment Program (GSNAP) (Wu and Nacu, 2010) along with 
Goby API support. The methylation rates for the two groups (NOD vs. NOR) were 
determined using the Goby package and differentially methylated regions (DMRs) across 
the groups were determined using the BSmooth, a replicate-aware program that accounts 
for biological variation by performing local smoothing of the data (Hansen et al., 2012), 
followed by a two-tailed t-test for DMR detection with P = 0.025. We focused our DMR 
analysis only on the CpG sites, and only sites with a minimum 10-fold coverage in at 
least 3 of the 4 samples in each group were considered for the analysis. 
 
Integration with human data. A total of 478 genes within 52 mouse orthologous 
regions associated with 49 human T1D loci were obtained from the T1DBase (Burren et 
al., 2011). This gene set was parsed to extract 312 protein-coding genes. These positional 
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candidate genes were used as input into the RNA-Seq and methylation datasets and 
evaluated for any significant differences with threshold of DESEQ P < 0.05 using the R 
software. 
 
Pathway analyses and heat maps. Pathway analyses were performed using the 
Ingenuity Pathway Analysis (Ingenuity Systems) and DAVID (NIH). Heatmaps were 
generated by normalizing FPKM values to the row mean and standard deviation values 










Figure 3-1. Gene expression changes in the 4-week-old NOD islets are involved in 
immune response signaling. 
Significant IPA canonical pathways enriched in 1745 genes differentially expressed in 
the NOD islets (DESEQ P < 0.05). Numbers under each pathway represents Fisher’s 
Exact P value to score enrichment density of the gene sets in a pathway. N = 6 for NOD 







Figure 3-2. Human positional candidate genes differentially expressed in NOD islets.  
Heatmap depicts the expression profiles of 30 positional candidate genes in NOD and 
NOR islets. Each column is one biological replicate (NOD, N=6; NOR, N=3). Colors 
represent transcripts upregulated (green) or downregulated (red), scaled to row Z-scores. 
The table catalogs gene symbol, full name, log-2 ratio of NOD baseMean to NOR 
baseMean fold change from DESEQ analysis, P value from DESEQ analysis, and the 
corresponding human T1D susceptibility locus. Genes in bold have not been previously 





Table 3-1. Differentially methylated genes in NOD islets  
Gene Change NOD NOR Description DM 
Hypermethylated  
Arrb2 0.17 0.34 0.17 arrestin, beta 2 * 
Masp2 0.14 0.53 0.40 mannan-binding lectin serine peptidase 2  
Cux1 0.10 0.19 0.08 cut-like homeobox 1  
      
Hypomethylated  
Gm7120 -0.18 0.68 0.86 predicted gene 7120  
Eif5a -0.13 0.30 0.43 eukaryotic translation initiation factor 5A * 
Plscr3 -0.38 0.35 0.72 phospholipid scramblase 3  
Erbb2ip -0.20 0.47 0.67 Erbin  
Dusp10 -0.24 0.70 0.94 dual specificity phosphatase 10  
Mrpl14 -0.18 0.53 0.71 mitochondrial ribosomal protein L14  
Tmem63b -0.18 0.53 0.71 transmembrane protein 63b  
Asgr2 -0.43 0.42 0.85 asialoglycoprotein receptor 2  
Zfp664 -0.12 0.47 0.59 zinc finger protein 664  
Neurl4 -0.18 0.30 0.48 neuralized E3 ubiquitin protein ligase 4  
Plekha2 -0.25 0.52 0.78 pleckstrin homology domain containing, A2  
Pex14 -0.27 0.47 0.74 peroxisomal biogenesis factor 14  
Lbr -0.25 0.55 0.81 lamin B receptor  
Mbnl2 -0.17 0.70 0.87 muscleblind-like 2  
Mgl1 -0.27 0.53 0.80 macrophage N-acetyl-galactosamine specific lectin  
BC025816 -0.17 0.60 0.78 kelch-like 36  
Galnt13 -0.16 0.35 0.51 N-acetylgalactosaminyltransferase 13  
Eif4a1 -0.14 0.32 0.45 eukaryotic translation initiation factor 4A1  
Upf1 -0.13 0.71 0.84 UPF1 regulator of nonsense transcripts homolog  
Col1a1 -0.17 0.60 0.77 collagen, type I, alpha 1  
Mylc2pl -0.13 0.38 0.52 myosin, light chain 10  
Foxa2 -0.14 0.38 0.51 forkhead box A2 * 
Gdf11 -0.17 0.34 0.50 growth differentiation factor 11   
Cd37 -0.10 0.50 0.61 CD37 antigen  
Osmr -0.15 0.66 0.80 oncostatin M receptor  
Git2 -0.26 0.54 0.80 G protein-coupled receptor kinase-interactor 2  
Stpg1 -0.25 0.45 0.70 sperm tail PG rich repeat containing 1  
Fat1 -0.12 0.79 0.90 FAT atypical cadherin 1  
Pcdh1 -0.32 0.52 0.85 protocadherin 1  
Ryr1 -0.25 0.54 0.79 ryanodine receptor 1 * 
Trpc2 -0.28 0.47 0.75 transient receptor potential cation channel, C2  
Nosip -0.18 0.45 0.63 nitric oxide synthase interacting protein  
Cacng4 -0.17 0.66 0.82 calcium channel, voltage-dependent, g4  
Atp6v0a2 -0.19 0.49 0.68 ATPase, H+ transporting, lysosomal V0 subunit a2  
Lyl1 -0.20 0.20 0.40 lymphoblastic leukemia associated 1  
Table categorizes genes that are hypo- and hypermethylated in the NOD islets compared 
to the NOR islets (N=4 each). NOD and NOR columns list the ratio of CpG methylation 
per region, and change is the mean difference in the ratios. Asterisk (*) in DM category 
indicates that the gene has been previously linked to diabetes or beta cell function. Rows 

















With guidance of Dr. Lori Sussel, I generated all data. NOD islet microarray data 






Results and Discussion 
Protein tyrosine phosphatase N2 (PTPN2) modulates hypoxia-inducible factor 1 
alpha/pyruvate kinase M2 (HIF-1α/PKM2) regulated gene expression in the beta cells 
after the onset of diabetes (Chapter 2). To determine whether this is a phenomenon 
specific to the streptozotocin (STZ) treated mice, we performed in silico analysis of the 
HIF-1α/PKM2 target genes using the islet gene expression data from NOD mice of 
various ages from Carrero et al (Carrero et al., 2013). Although almost all of the genes 
were not significantly changed by statistical methods, analysis of relative expression 
revealed subtle but progressive increases in many of the HIF-1α/PKM2 target genes with 
increasing age, reaching maximum expression in diabetic islets (Fig. 4-1). We compared 
this NOD islet gene expression data to our RNA-Seq data from STZ-diabetic Ptpn2 βKO 
and control islets in the context of HIF-1α/PKM2 target genes. We confirmed that the 
Ptpn2 βKO islets clustered more tightly with the diabetic NOD islets and that the control 
islets from our study clustered tightly with younger NOD islets (Fig. 4-2), perhaps 
reflecting the fact that Ptpn2 βKO animals are more severely diabetic. This indicates that 
the upregulation of HIF-1α/PKM2 target genes is a conserved feature of diabetic islets 
and suggests that greater increases in HIF-1α/PKM2 target genes may be an indication of 
exacerbated disease progression in islets.   
We also analyzed the HIF-1α/PKM2 target gene expression in the prediabetic 4-
week-old NOD islets (RNA-Seq data from Chapter 3). There was no obvious trend or 
differences in the NOD compared to the NOR islets at this early time point, but 
surprisingly, Pkm2 expression was significantly upregulated in the 4-week-old NOD 
islets (Fig. 4-3). Re-examining the time-course NOD islet expression data from Carrero et 
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al, we found that Pkm2 expression was comparable among the NOD and age-matched 
control islets at 6 weeks. However, the control strains in this study were NOD.Rag1-null, 
B6.g7, and C57BL/6J strains (Carrero et al., 2013). None of these strains develop insulitis 
similar to the NOD mice, as the NOD.Rag1-null mice are NOD congenic strain without 
the adaptive immune system, B6.g7 strain is the C57BL/6J strain carrying the NOD-
matched H2g7 histocompatibility locus, and the C57BL/6J strain is the normal wildtype 
strain. In our study, we used the NOR strain, which is the NOD congenic strain that 
accumulates pancreatic leukocytic aggregates (peri-insulitis) without becoming diabetic. 
Furthermore, the NOR strain is completely resistant to cyclophosphamide-induced 
diabetes (Prochazka et al., 1992; Serreze et al., 1994), suggesting that even in the face of 
heightened immune or chemical attack, the islets in this strain resist cell death. Our 
finding that Pkm2 expression was significantly upregulated in the NOD islets compared 
to the NOR islets suggests that NOR islets resist diabetes possibly because they express 
less PKM2 and thus may have blunted expression of HIF-1α/PKM2 target genes critical 







Figure 4-1. In silico analysis of HIF-1α/PKM2 gene expression pattern in NOD islets 
of different ages. 
Analysis of time-course NOD islet microarray for HIF-1α/PKM2-responsive genes, 
represented as a heatmap of relative microarray intensities. Diabetic islets (3 lanes at the 
right) cluster tightly together and have increased HIF-1α/PKM2-responsive transcription. 







Figure 4-2. Integration of Ptpn2 βKO islet RNA-Seq data with the NOD islet 
microarray in silico analysis. 
Hierarchical clustering analysis of the HIF-1α/PKM2-responsive genes in time-course 
NOD islet microarray data and the RNA-Seq of islets from both unstressed and STZ-
administered Ptpn2 βKO (KO and STZ-KO) and control (Ctrl and STZ-Ctrl) mice is 
shown. Because microarray intensities and RNA-Seq FPKM values are not directly 
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comparable, relative Z-scores were calculated within each datasets, which were then 
combined to generate the heatmap. Three major clusters are separated. The first cluster 
contains mostly NOD control islets (6-week-old NOD.Rag1-null, NODRAG6; 6-week-
old B6.g7, B6G6; and 6-week-old C57BL/6J, C57BL6), NOD islets from 4-6 weeks of 
age (NOD4 and NOD6), and unstressed KO (YL04-06) and Ctrl islets (YL01-03). The 
second cluster contains prediabetic NOD samples (8-, 12-, and 18-week-old, NOD8, 
NOD12, and NOD18) and STZ-Ctrl islets (YL09 and 10). The last cluster contains 
diabetic NOD samples (NOD_D) and STZ-KO islets (YL07 and 08). Microarray raw 







Figure 4-3. Pkm2 expression in 4-week-old NOR and NOD islets. 
The expression of Pkm2 from RNA-Seq is shown (Chapter 3). DESEQ analysis identified 
Pkm2 as being differentially expressed in the NOD islets at this time point (P = 0.002). 
Hierarchical clustering reveals that 4 of the NOD samples cluster with NOR samples; 
interestingly, 3 of these samples clustering with NOR were from male NOD mice that 
have a lower incidence of T1D (NOD female N = 7, NOD male N = 8, NOR female N = 
























Islet sample preparation, methylation sequencing, and RNA-Seq same as Chapter 3. 





Results and Discussion 
Cytosine methylation in mammalian DNA is a key epigenetic modification 
controlling chromatin structure (Bird and Wolffe, 1999). While most of the DNA 
methylation is found on CpG dinucleotides, non-CpG methylation has been observed. 
One study reported that the majority of all DNA methylation was at non-CpG nucleotides 
in the human spleen (Woodcock et al., 1987). A more recent study reported non-CpG 
methylation in mammalian cell lines and posited that non-CpG methylation is commonly 
underestimated due to current methylation analysis methods (Yan et al., 2011). Another 
study reported de novo DNA methylation at both CpG and non-CpG dinucleotides in the 
promoter of adenovirus type 2 after integration into host genome, suggesting such 
propagation of de novo methylation in response to viral infection may hinder the 
expression of integrated foreign DNA (Toth et al., 1990).  
To address the question of whether non-CpG methylation influences islet gene 
expression, we analyzed the existence of CpT methylation in our reduced representation 
bisulfite sequencing (RRBS) data from non-obese diabetic (NOD) and non-obese insulitis 
resistant (NOR) islets (Chapter 3). Surprisingly, we discovered that there were 4654 
differentially methylated CpT sites in the NOD and NOR islets (DMR P < 0.05). To 
determine whether any of the CpT methylation correlated with gene expression data, we 
combined the list of candidate genes with promoter CpT methylation differences with the 
list of 658 genes with significantly different gene expression (RNA-Seq data from 
Chapter 3, with adjusted P < 0.05) and found that of 109 genes appeared in both 
candidate lists. Of these, 46 genes had correlating inverse relationship between gene 
expression and promoter methylation. All 46 genes were CpT-hypomethylated in the 
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NOD islets and had increased gene expression, and no candidate gene displayed 
hypermethylation and reduced gene expression (Table 5-1; Fig. 5-1A). Interestingly, one 
of the genes was chromogranin A (Chga), which is a T1D autoantigen specifically 
recognized by self-reactive T cells (Stadinski et al., 2010). 
We then analyzed whether a majority of these candidate genes were involved in a 
common signaling pathway. Interestingly, the most significantly changed category was 
endoplasmic reticulum (ER) stress pathway, which has been shown to precede islet 
inflammation and the onset of hyperglycemia in the NOD mice (Ize-Ludlow et al., 2011; 
Tersey et al., 2012). We performed quantitative PCR analysis with NOD and NOR islet 
RNA and successfully validated the RNA-Seq findings (Figure 5-1B). Given that the 
NOD islets develop ER stress signatures as early as 6 weeks, the lack of CpT methylation 
at the promoters of key ER stress genes may facilitate the aberrant overexpression of 
these genes even earlier than 6 weeks, as our samples are from 4-week-old mice. Whether 
the CpT methylation is maintained over time until the onset of hyperglycemia in NOD 
mice has not yet been investigated, but our study highlights that non-CpG methylation 
events may be important for the regulation of gene expression in islet cells.  
It is not known whether non-CpG methylation is found in clusters as in CpG 
islands. A global bisulfite sequencing strategy would detect all non-CpG methylation 
events. Our study was somewhat limited in that the original RRBS library for the 
methylation sequencing was a method to enrich for CpG islands by CpG-specific 
enzymatic cleavage of the genome. However, even if our study has only detected 
differential CpT methylation near CpG islands, the fact that we detected correlating 
changes in ER stress genes and Chga suggests that a global analysis of CpT methylation 
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and other non-CpG methylation events may be functionally significant in understanding 







Figure 5-1. Gene expression of candidates with CpT methylated promoters.  
(A) 46 candidate genes with correlating changes in RNA expression and CpT methylation 
(presumed inverse relationship) were all highly expressed and had hypomethylated loci in 
the NOD islets. Islet RNA-Seq data for the 46 genes shown as a heatmap. F and M 
indicate female and male gender of the mouse (NOR M, N =4; NOR F, N = 3; NOD M, 
N = 7; NOD F, N = 6). Full list of genes is in Table B-1. (B) Validation qPCR analysis 
using fresh islet RNA from 4-week-old female NOD and NOR mice, normalized to Hprt 

















Chga 0.0001 1.43 0.0081 -2.05 chromogranin A 
Pyy <0.0001 1.43 0.0007 -1.82 peptide YY 
Pdia6 0.0488 1.29 0.0202 -1.87 protein disulfide isomerase associated 6 











v-maf avian musculoaponeurotic 











ER degradation enhancer, mannosidase 
alpha-like 2 
Pdia4 0.0272 1.33 0.0052 -1.93 protein disulfide isomerase associated 4 
Vdr 0.0333 1.33 0.0237 -1.96 vitamin D receptor 
KIAA0513 0.0252 1.31 0.0125 -1.94 RIKEN cDNA 6430548M08 
Creld2 0.0083 1.40 <0.0001 -2.70 cysteine-rich with EGF-like domains 2 
Akp3 <0.0001 28.69 0.0215 -4.41 alkaline phosphatase 3 
Peg10 <0.0001 2.04 0.0084 -1.71 paternally expressed 10 
Ckb 0.0002 1.52 0.0071 -2.35 creatine kinase, brain 











ganglioside induced differentiation 
associated protein 2 
Mthfr <0.0001 1.62 0.0473 -1.95 5,10-methylenetetrahydrofolate reductase 
Myo1d <0.0001 1.66 0.0304 -1.73 myosin ID 
Rps6ka2 0.0327 1.37 0.0338 -1.90 ribosomal protein S6 kinase 2 
Ncald 0.0149 1.41 0.0456 -1.77 neurocalcin delta 
Tuba4a 0.0173 1.43 0.0046 -1.81 tubulin, alpha 4a; tubulin, alpha 4A 
Ctnnal1 0.0049 1.45 0.0347 -2.16 catenin, alpha like 1 
Arhgap18 <0.0001 8.05 0.0155 -2.34 Rho GTPase activating protein 18 
Mttp 0.0003 1.67 0.0167 -1.46 microsomal triglyceride transfer protein 
Mgp 0.0001 1.70 0.0110 -2.67 matrix Gla protein 
Ckmt1 0.0015 1.56 0.0319 -2.07 creatine kinase, mitochondrial 1 
Ovol2 <0.0001 4.87 0.0087 -1.43 ovo-like 2 
Cnnm1 0.0005 1.96 0.0088 -2.14 cyclin M1 
Nfil3 0.0001 2.23 0.0124 -1.88 nuclear factor, interleukin 3 
Cry1 0.0017 1.78 0.0471 -1.99 cryptochrome circadian clock 1 
Pak1 0.0461 1.59 0.0014 -2.03 p21 protein (Cdc42/Rac)-activated kinase 1 
Fam159b 0.0075 1.81 0.0125 -1.59 family with sequence similarity 159B 
Cbln4 0.0027 2.35 0.0119 -1.67 cerebellin 4 precursor 
Tgfb3 0.0078 1.90 0.0414 -1.98 transforming growth factor, beta 3 
Myo1a <0.0001 17.54 0.0041 -2.65 myosin IA 
Prtg <0.0001 9.35 0.0399 -1.36 protogenin 
Myo7b 0.0004 3.05 0.0475 -1.89 myosin VIIB 
Cybrd1 <0.0001 6.15 0.0297 -1.34 cytochrome b reductase 1 
L1td1 <0.0001 12.46 0.0007 -1.92 LINE-1 transposase domain containing 1 
Cxcl10 0.0011 8.28 0.0028 -1.62 chemokine (C-X-C motif) ligand 10 
Sectm1b 0.0007 7.58 0.0385 -2.44 secreted and transmembrane 1B 
Rmrp 0.0031 8.40 0.0001 -2.53 RNA of mitochondrial RNAase P 
Ankrd1 0.0459 4.05 0.0009 -1.71 ankyrin repeat domain 1 
Rpph1 0.0021 14.81 0.0001 -2.31 ribonuclease P RNA component H1 











undifferentiated embryonic cell 
transcription factor 1 
Nlrp6 0.0207 7.17 0.0378 -1.37 NLR family, pyrin domain containing 6 
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Table 5-1. Genes with differential CpT methylation and RNA expression.  
Table categorizes genes that are hypo- and hypermethylated at the CpT sites in the NOD 
islets compared to the NOR islets (N = 4 each). RNA P and fold change are the adjusted 
P value and the ratio of NOD to NOR baseMean values from DESEQ analysis. CpT P 
and delta mCpT are the Fisher P value and the mean difference in the ratio of CpT 



















Dissertation summary and major findings 
Type 1 diabetes (T1D) is a chronic disease characterized by the autoimmune 
attack on pancreatic beta cells leading to substantial beta cell loss and the inability to 
maintain glucose homeostasis. I have sought to identify novel mediators of beta cell loss 
that are specific to the beta cell as opposed to the autoreactive immune system. In 
Chapter 2, analysis of the Ptpn2 βKO islets compared to the control islets after 
streptozotocin administration revealed a novel mode of beta cell loss by a beta cell-
intrinsic mechanism of nuclear accumulation of PKM2, which is modulated by the T1D 
candidate PTPN2. My study suggests that PKM2 hyperaccumulation in the nuclei of 
Ptpn2 βKO beta cells leads to increased apoptosis signaling and preventing PKM2 
nuclear accumulation may be a solution to preventing insulitic injury. Furthermore, in the 
insulitis-prone NOD genetic background, the NOD beta cells with higher expression of 
Pkm2 are sensitive to insulitis, and congenic NOR beta cells with lower expression of 
Pkm2 are resistant to insulitis, suggesting a possible mechanism for the NOR beta cells to 
escape insulitic injury and diabetes by having a desensitized system of PKM2-mediated 
apoptosis signaling (Chapter 4). In Chapter 3, global gene expression profiling and 
promoter CpG methylation analysis of NOD and NOR islets at a time point prior to 
insulitis, coupled with T1D loci from human genome-wide association studies, have 
revealed novel candidate genes that may be involved in beta cell-mediated pathogenesis 
of T1D. In Chapter 5, analysis of the CpT methylation profiles suggests that non-CpG 
methylation may also play a role in regulating differential gene expression in the NOD 
and NOR islets. Together, my studies contribute to identifying beta cell-centric 
mechanisms of T1D through a combination of candidate-based and global inquiries.  
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Integration of the signaling pathways affected by the loss of PTPN2 through PKM2 
During the analysis of Ptpn2 βKO and control islet transcriptomes, mammalian 
target of rapamycin (mTOR) was highly upregulated in the Ptpn2 βKO islets in both the 
unstressed and stressed conditions. It is unknown how PTPN2 regulates mTOR signaling 
and how this contributes to beta cell loss or dysfunction in diabetes pathogenesis. 
PTPN2-deficient beta cells overexpress the upstream activator of mTOR, ras homolog 
enriched in brain (Rheb), but how does the lack of PTPN2 translate to increased 
expression of Rheb transcripts? Are there transcription factors that are regulated by 
PTPN2-mediated tyrosine dephosphorylation? Does PTPN2 also inhibit mTOR directly? 
Or does PTPN2-catalyzed dephosphorylation of phosphotyrosine residues facilitate 
serine/threonine phosphorylation by mTOR, as differential phosphorylation of serine or 
tyrosine residues can compete for positive or negative regulation of signal transduction 
pathways, which is a layer of regulation of insulin receptor substrate 1 by mTOR (Ozes et 
al., 2001). Moreover, how does the relationship of PTPN2 and mTOR contribute to the 
regulation of nuclear PKM2? Further studies are needed to address these questions. For 
example, one could use rapamycin to inhibit mTOR in the Ptpn2 βKO and control islets, 
with or without prior stress with STZ, and assess global changes in the 
phosphoproteomes. Another approach to address these questions may be to generate beta 
cell-specific double knockout mice with the genetic deletion of both Ptpn2 and an 
activator of mTOR such as Rheb.  
The crossover of mTOR and PKM2 deserves our attention. It has been shown that 
mTOR can upregulate Pkm2 transcription in cancer cells through a downstream effector 
MYC, which can activate the transcription of hnRNP proteins that play a role in 
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preferential alternative splicing of Pkm2 (Sun et al., 2011). This may be a self-
perpetuating feedback loop, since PKM2 can phosphorylate histone H3 to drive the 
transcription of Myc (Yang et al., 2012a). In my study, Myc was highly upregulated in the 
unstressed Ptpn2 βKO islets (DESEQ P = 0.01, fold change = 2.24), and although it did 
not reach statistical significance, the upregulation of Myc was also present in the STZ-
stressed Ptpn2 βKO islets (DESEQ P = 0.23, fold change = 3.01). The expression of 
Pkm2 was not different between Ptpn2 βKO and control islets, but we cannot rule out 
mTOR/MYC-mediated Pkm2 expression in the Ptpn2 βKO islets at a more acute time 
point. Another study implicated microRNA miR-99a in regulating the mTOR/PKM2 axis. 
In cancer cells, insulin decreased miR-99a expression, which was accompanied by 
increased mTOR, HIF-1α, and PKM2; and the overexpression of miR-99a abrogated the 
insulin-mediated upregulation of PKM2 and HIF-1α, similar to rapamycin treatment in 
these cells (Li et al., 2013). If mTOR-mediated beta cell proliferation and apoptosis were 
to be compared with mTOR signaling in tumor cells, it is possible that mTOR activation-
mediated increases in Pkm2 and HIF-1α signaling after stressful stimuli in the beta cells 
could lead to beta cell proliferation or apoptosis. My data suggests that PKM2 nuclear 
translocation is accompanied by increased beta cell loss and exacerbated survival, 
suggesting that in our case, mTOR/PKM2/HIF-1α is involved in beta cell apoptosis, 
counteracted by PTPN2.  
In addition mTOR signaling, I have observed hyperphosphorylation of STAT3 in 
the Ptpn2 βKO islets, which was supported by the recent panc-TCPTP KO study (Xi et 
al., 2014). mTOR positively regulates STAT3 to mediate tumorigenesis (Zhou et al., 
2007), PKM2 can act as a kinase to mediate STAT3 phosphorylation (Gao et al., 2012), 
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and together with decreased PTPN2-mediated dephosphorylation of STAT3, mTOR and 
PKM2 may compound the hyperactivation of STAT3 in the Ptpn2 βKO islets. It is 
interesting to note that in addition to its role in beta cell function, STAT3 is activated in 
response to the inflammatory cytokine interleukin 22 (IL-22) and it helps mucosal wound 
healing upon injury in cell types targeted by other autoimmune diseases, such as the 
intestinal epithelial cells in inflammatory bowel disease (Pickert et al., 2009).  
IL-22 is secreted by the immune cells, and IL-22 was highly upregulated in islets 
from recently-diagnosed T1D donors, suggesting that IL-22 signaling may be upregulated 
in response to islet cell injury (Arif et al., 2011). Therefore, much like its role in aiding 
epithelial barrier healing, STAT3 hyperactivation may be protective in the beta cells. 
However, exposure to interferon alpha (IFN-α) can activate STAT1, mediated by IL-22 
signaling, and the increase in IL-22 in T1D islets may indicate STAT1 activation rather 
than STAT3 (Arif et al., 2011; Bachmann et al., 2013). IFN-α and STAT1 activation have 
been linked to T1D initiation, and beta cell PTPN2 has been shown to dephosphorylate 
both STAT1 and STAT3 (Li and McDevitt, 2011; Moore et al., 2011; Xi et al., 2014), 
suggesting that IL-22-mediated potentiation of STAT1 signaling by IFN-α may be 
another avenue of cellular defense regulated by PTPN2. Furthermore, beta cells express 
high levels of IL-22 receptor IL-22R1 (Shioya et al., 2008), and in my studies, I have 
found that Il22ra1 expression is significantly increased in the unstressed Ptpn2 βKO 
islets (DESEQ P = 0.016). In the STZ-stressed islets, Il22ra1 is not differentially 
expressed, but Il22ra2, encoding another IL-22 receptor, is highly expressed in the Ptpn2 
βKO islets (DESEQ P = 0.007), again suggesting that IL-22 signaling, and perhaps also 
STAT1-mediated apoptosis signaling, may be increased in the Ptpn2 βKO islets, much 
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like the increased IL-22 levels in the islets of the T1D patient (Arif et al., 2011). 
Moreover, IL22RA2 has been shown to mediate both wound healing and tumorigenesis 
after chronic inflammation (Huber et al., 2012), highlighting the parallel between cancer 
cells and apoptotic cells upon inflammatory signaling.  
It is unclear how the crosstalk between PTPN2, PKM2, mTOR, STAT3, and 
STAT1 contributes to beta cell apoptosis, and several questions remain unanswered. 
Does the kinase function of PKM2 extend to the phosphorylation of STAT1 in addition to 
STAT3? Does STAT3 hyperactivation facilitate STAT1-mediated apoptosis signaling 
observed in PTPN2-knockdown beta cells (Santin et al., 2011)? Does increased IL-22 in 
T1D islets potentiate STAT1 and STAT3, or preferentially activate one versus the other? 
Does PTPN2-mediated nuclear export of PKM2 ameliorate STAT1-mediated apoptosis 
in beta cells, or is nuclear PKM2-responsive transcription of apoptotic genes independent 
of STAT1-mediated apoptosis? PKM2, mTOR, STAT3, and PTPN2 have all been 
implicated in tumorigenesis, but how does their interaction result in beta cell loss, while 
mediating proliferative, pro-survival signaling in tumor cells? Further investigation into 
the coordinated regulation of mTOR, STATs, and PKM2 by PTPN2 will be illuminating 
for both diabetes and cancer. 
 
Diabetes to cancer, and the therapeutic implications of this work 
Parallels between diabetes and cancer can be seen in many facets of my study, 
including mTOR, STAT3, HIF-1α, and PKM2. Another parallel can be seen in the mode 
of diabetes induction in my studies. I used STZ to induce diabetes, but STZ has been 
shown to induce beta cell tumors, known as insulinomas (Kazumi et al., 1978; Rakieten 
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et al., 1971; Yamagami et al., 1985). A significant portion of the mice surviving a single 
low-dose injection of STZ over 10 months (42%) went on to develop insulinomas. It has 
been suggested that poly(ADP-ribose) synthase is activated in response to DNA 
fragmentation induced by STZ, which leads to the depletion of NAD+ that is 
incompatible with beta cell survival, and combination of STZ with inhibitors of 
poly(ADP-ribose) synthase potentiates STZ-mediated insulinoma incidence (up to 100% 
after 10 months). However, STZ alone can mediate tumorigenesis in the beta cells, which 
suggests that islet cells that survive the apoptotic stimuli eventually succeed in 
proliferating and surviving through poly(ADP-ribose) synthase-independent pathway, 
perhaps through the accumulation of nuclear PKM2, which can mediate both apoptosis 
and tumorigenesis.  
PTPN2 is another example of convergence between oncogenic and apoptotic 
signaling. Although there is no evidence of PTPN2 deletion in insulinoma patients, 
inactivating mutations or deletion of PTPN2 can result in Hodgkin’s lymphoma or T-cell 
acute lymphoblastic leukemia (T-ALL), which has been attributed to the disinhibition of 
JAK1 signaling (Kleppe et al., 2010; Kleppe et al., 2011b). It is possible that in addition 
to JAK1 regulation, PTPN2 is required to mediate the nuclear export of PKM2, which 
can inhibit carcinogenesis. Further study will be required to determine if this is the case.  
It remains to be seen whether beta cell-specific ablation of Pkm2 influences beta 
cell loss or function. I have recently begun to investigate this by obtaining the Pkm2 fl/fl 
mouse and crossing it to the RIP-Cre mice. If nuclear PKM2-mediated apoptotic 
transcriptional reprogramming is required for beta cell loss in T1D, beta cells with Pkm2 
deletion could be resistant to diabetes, as in the NOR strain, which we have shown to 
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have decreased Pkm2 transcript levels and is known to be insulitis-resistant despite the 
accumulation of pancreatic immune infiltrates (Prochazka et al., 1992). Alternatively, 
Pkm2 deletion could result in contradicting phenotypes, as in the beta cell-specific HIF-
1α knockout mice, due to the duality of PKM2 function in cell proliferation and cell 
death. Accordingly, in cancer cells, Pkm2 deletion resulted in a different ratio of high- to 
low-proliferation cells in the tumor, but cancer formation or progression was not 
significantly affected (Israelsen et al., 2013).  
In place of tissue-specific genetic ablation of Pkm2, which is impossible in 
humans as a therapeutic approach, PKM2 can be regulated by shifting the ratio of 
tetramer-to-dimer conformation through small molecule activators of PKM2 such as 
TEPP46, which was utilized in my studies. In proliferating cell types, nuclear PKM2 
mediates proliferation, and PKM2 activator treatment has resulted in increased cell death 
in vitro (Anastasiou et al., 2011) and delayed xenograft tumor growth in vivo in a multi-
day dosing regimen without any toxicity or weight loss in mice (Anastasiou et al., 2012). 
In my study, in nonproliferating islets, cytotoxic stressor-mediated increase in apoptotic 
transcripts were downregulated upon co-treatment with TEPP46, suggesting that in cell 
types where PKM2 mediates apoptosis, PKM2 activators may be useful for decreasing 
cell death signaling. This suggests a potential avenue for testing whether the in vivo 
administration of PKM2 activators would prevent or delay diabetes in diabetes-prone 
mice, such as the NOD strain.  
Similar to the ability of TEPP46 to stabilize cytosolic PKM2, inhibiting the 
nuclear import of PKM2 may be another approach to prevent insulitic injury. In one 
study, a small molecule inhibitor of nuclear import was shown to prevent diabetes and 
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attenuate insulitis in the pancreas of NOD mice, which was attributed to the inhibition of 
nuclear import of stress-responsive transcription factors such as NF-κB in the immune 
cells, resulting in decreased activation of immune cells (Moore et al., 2010). However, 
the study does not address the attenuation of nuclear import of stress-responsive 
transcription factors in the beta cells leading to apoptosis. It is my belief that the nuclear 
import inhibitor used in this study may have prevented beta cell loss partly by inhibiting 
the nuclear import of PKM2 in the beta cells. Additional studies using nuclear import 
inhibitors is crucial in determining whether this is a viable therapeutic strategy for 
preventing beta cell loss.  
 
HIF-1α/PKM2-responsive genes in human T1D 
In this study, I show that exacerbated beta cell loss in PTPN2-deficient beta cells 
is accompanied by a significant upregulation of HIF-1α/PKM2-driven genes, and that 
decreased expression of Pkm2 in the NOR islets could be a reflection of attenuated beta 
cell apoptotic response. However, human and mice are inherently different, as seen in the 
differences between T1D pathogenesis in humans and the NOD mouse model (discussed 
in Chapter 1). Therefore, I investigated whether the upregulation of HIF-1α/PKM2 target 
genes is observed in the human diabetic islets. Unfortunately, global gene expression data 
of islets from human T1D patients do not exist yet. The closest approximation to T1D 
islet gene expression data is provided by the RNA-Seq data from human islets treated 
with pro-inflammatory cytokines (Eizirik et al., 2012). I performed in silico analysis of 
select HIF-1α/PKM2 target genes, and our results demonstrate that these genes are highly 
upregulated in the cytokine treated human islets (Fig. 6-1). Further study with primary 
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islets needs to be performed to address whether the HIF-1α/PKM2 target gene expression 
is regulated by PTPN2 in human beta cells, and whether PKM2 accumulates in the nuclei 
of diabetic beta cells at the initiation of T1D and whether this accumulation persists 
throughout disease progression. It is highly probable that PTPN2 mediated regulation of 
nuclear accumulation of PKM2 is also a mechanism of human beta cell loss, given that 
the original identification of PTPN2 as a T1D candidate gene was from human genome-
wide association studies.  
 
Conclusions 
T1D is a chronic disease characterized by progressive beta cell loss and the 
inability to maintain glucose homeostasis. To prevent beta cell loss and disease 
progression, it is critical to understand the mechanisms of beta cell defense. My thesis 
work provides a foundation for further understanding of beta cell-intrinsic factors that 
may be responsible for cell survival or death upon cytotoxic stimuli. The fact that PKM2 
accumulates in the diabetic beta cells and that nuclear PKM2-mediated activation of pro-
apoptotic transcripts may be a novel mechanism of beta cell loss have never been shown. 
Furthermore, through the global approach, I have discovered novel candidate genes that 
may be critical for beta cell defense or survival, functional studies of which may uncover 
additional mechanisms of beta cell loss that may be targeted for developing T1D 
therapies. Finally, my dissertation has bridged diabetes and cancer pathogenesis through 
a single molecule, PKM2, through the investigation of T1D candidate PTPN2, and 
figuring out how to prevent the nuclear accumulation of PKM2 may be the system 






Figure 6-1. In silico analysis of RNA-Seq data from human islets treated with pro-
inflammatory cytokines.  
Analysis of human islet RNA-Seq, represented as a heatmap. Three transcripts from the 
PKM locus were detected, with transcript variant 1 encoding PKM2 (RefSeq ID, 
NM_002654) and variants 2 and 3 encoding PKM1 (RefSeq IDs, NM_182470 and 
NM_182471, indicated as PKM1.2 and PKM1.3 in the heatmap, respectively). Some of 
the HIF-1α/PKM2-responsive genes are shown. Four different transcript variants of 
LDHA were detected, but only the most highly expressed transcript variant (RefSeq ID, 
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